WO2022125562A1 - Peptide compositions and methods for anti-cd3 binding domains - Google Patents

Peptide compositions and methods for anti-cd3 binding domains Download PDF

Info

Publication number
WO2022125562A1
WO2022125562A1 PCT/US2021/062233 US2021062233W WO2022125562A1 WO 2022125562 A1 WO2022125562 A1 WO 2022125562A1 US 2021062233 W US2021062233 W US 2021062233W WO 2022125562 A1 WO2022125562 A1 WO 2022125562A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
complex
isolated polypeptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/062233
Other languages
English (en)
French (fr)
Inventor
David Campbell
Thomas R. DIRAIMONDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janux Therapeutics Inc
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Priority to JP2023534635A priority Critical patent/JP2024500335A/ja
Priority to MX2023006733A priority patent/MX2023006733A/es
Priority to US18/256,278 priority patent/US20240043536A1/en
Priority to EP21904260.3A priority patent/EP4259177A4/en
Priority to CA3201401A priority patent/CA3201401A1/en
Priority to AU2021396507A priority patent/AU2021396507A1/en
Priority to KR1020237023034A priority patent/KR20230137301A/ko
Priority to CN202180092543.9A priority patent/CN116981682A/zh
Publication of WO2022125562A1 publication Critical patent/WO2022125562A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • polypeptides or polypeptide complexes comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2.
  • the peptide comprises the amino acid sequence of Peptide-1.
  • the peptide comprises the amino acid sequence of Peptide-2.
  • the peptide is connected to the anti-CD3 binding domain in a configuration according to: Ai-Li-Pi (Formula I) wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Ai comprises the anti-CD3 binding domain
  • Li comprises a cleavable linker that is a substrate for a tumor specific protease
  • Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Pi is connected N-terminal to the cleavable linker and Ai is connected C-terminal to the cleavable linker.
  • Pi is connected C-terminal to the cleavable linker and Ai is connected N-terminal to the cleavable linker.
  • Pi is bound to Ai through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof.
  • Ai is further linked to a tumor antigen binding domain (A2).
  • the polypeptide or polypeptide complex is according to Formula la: P2-L2-A2-A1-L1-P1 wherein P2 comprises a peptide that impairs binding of A2to a tumor antigen; and L2 comprises a second cleavable linker that connects A2to P2 and is a substrate for a tumor specific protease.
  • Ai comprises an antibody or antibody fragment.
  • Ai comprises an antibody or antibody fragment that is human or humanized.
  • Li is bound to N-terminus of the antibody or antibody fragment of Ai.
  • A2 is bound to N-terminus of the antibody or antibody fragment of Ai.
  • Li is bound to the C-terminus of the antibody or antibody fragment of Ai.
  • A2 is bound to the C- terminus of the antibody or antibody fragment of Ai.
  • the antibody or antibody fragment of Ai comprises a single chain variable fragment, a single domain antibody, or a Fab fragment.
  • Ai is the single chain variable fragment (scFv).
  • the scFv comprises a scFv heavy chain polypeptide and a scFv light chain polypeptide.
  • Ai is the single domain antibody.
  • the antibody or antibody fragment thereof comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a camelid derived single domain antibody.
  • Ai comprises an anti-CD3e single chain variable fragment.
  • Ai comprises an anti-CD3e single chain variable fragment that has a KD binding of 1 pM or less to CD3 on CD3 expressing cells.
  • Ai comprises a variable light chain and variable heavy chain each of which is capable of specifically binding to human CD3.
  • Ai comprises the scFv comprising a scFv heavy chain variable domain and an scFv light chain variable domain comprising complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC- CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; and HC-CDR3: SEQ ID NO: 5; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC- CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light
  • the polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease. In some embodiments, the polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease and Ai binds to the effector cell. In some embodiments, the effector cell is a T cell. In some embodiments, Ai binds to a polypeptide that is part of a TCR-CD3 complex on the effector cell. In some embodiments, the polypeptide that is part of the TCR-CD3 complex is human CD3s. In some embodiments, A2 comprises an antibody or antibody fragment.
  • the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment, a single domain antibody, Fab’, or a Fab.
  • the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a camelid derived single domain antibody.
  • the antibody or antibody fragment thereof of A2 is humanized or human.
  • A2 is the Fab or Fab’.
  • the Fab or Fab’ comprises (a) a Fab light chain polypeptide and (b) a Fab heavy chain polypeptide.
  • A2 comprises an epidermal growth factor receptor (EGFR) binding domain. In some embodiments, A2 comprises a carcinoembryonic antigen-related cell adhesion molecule CEACAM5 binding domain. In some embodiments, Pi is further linked to a half-life extending moiety (Hi). In some embodiments, the half-life extending moiety is a single-domain antibody. In some embodiments, Hi comprises a polymer. In some embodiments, the polymer is polyethylene glycol (PEG). In some embodiments, Hi comprises albumin. In some embodiments, Hi comprises an Fc domain. In some embodiments, the albumin is serum albumin. In some embodiments, the albumin is human serum albumin.
  • EGFR epidermal growth factor receptor
  • A2 comprises a carcinoembryonic antigen-related cell adhesion molecule CEACAM5 binding domain.
  • Pi is further linked to a half-life extending moiety (Hi). In some embodiments, the half-life extending moiety is a single-domain antibody. In some
  • Hi comprises a polypeptide, a ligand, or a small molecule.
  • the polypeptide, the ligand or the small molecule binds serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the circulating immunoglobulin comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • the serum protein is albumin.
  • the polypeptide is an antibody.
  • the antibody comprises a single domain antibody, a single chain variable fragment, or a Fab.
  • the single domain antibody comprises a single domain antibody that binds to albumin.
  • the single domain antibody is a human antibody or humanized antibody.
  • the single domain antibody is 645gHlgLl.
  • the single domain antibody is 645dsgH5gL4.
  • the single domain antibody is 23-13-A01 -sc02.
  • the single domain antibody is A10m3 or a fragment thereof.
  • the single domain antibody is DOM7r-31.
  • the single domain antibody is Alb-1, Alb-8, or Alb-23. In some embodiments, the single domain antibody is 10G or 10GE. In some embodiments, the single domain antibody is SA21.
  • the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified non-natural amino acid, or a combination thereof. In some embodiments, the modified amino acid or modified non- natural amino acid comprises a post-translational modification.
  • Hi comprises a linking moiety (L3) that connects Hi to Pi. In some embodiments, L3 is a peptide sequence having at least 5 to no more than 50 amino acids.
  • L3 is a peptide sequence having at least 10 to no more than 30 amino acids. In some embodiments, L3 is a peptide sequence having at least 10 amino acids. In some embodiments, L3 is a peptide sequence having at least 18 amino acids. In some embodiments, L3 is a peptide sequence having at least 26 amino acids.
  • L3 has a formula selected from the group consisting of (G 2 S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919) j and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of at least 1.
  • L3 comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • the Fab light chain polypeptide of A 2 is bound to a C-terminus of the single chain variable fragment (scFv) of Ai.
  • the Fab heavy chain polypeptide of A 2 is bound to a C-terminus of the single chain variable fragment (scFv) Ai. In some embodiments, the Fab light chain polypeptide of A 2 is bound to a N-terminus of the single chain variable fragment (scFv) of Ai. In some embodiments, the Fab heavy chain polypeptide of A 2 is bound to a N-terminus of the single chain variable fragment (scFv) Ai. In some embodiments, the Fab heavy chain polypeptide of A 2 is bound to the scFv heavy chain polypeptide of Ai. In some embodiments, the Fab light chain polypeptide of A 2 is bound to the scFv heavy chain polypeptide of Ai.
  • the Fab heavy chain polypeptide of A 2 is bound to the scFv light chain polypeptide of Ai. In some embodiments, the Fab light chain polypeptide of A 2 is bound to the scFv light chain polypeptide of Ai. In some embodiments, the Fab heavy chain polypeptide of A 2 is bound to the scFv heavy chain polypeptide of Ai and L 2 is bound to the Fab light chain polypeptide of A 2 . In some embodiments, the Fab light chain polypeptide of A 2 is bound to the scFv heavy chain polypeptide of Ai and L 2 is bound to the Fab heavy chain polypeptide of A 2 .
  • the Fab heavy chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab light chain polypeptide of A2.
  • the Fab light chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab heavy chain polypeptide of A2.
  • P2 impairs binding of A2to the tumor antigen.
  • P2 is bound to A2 through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H- bonding interactions, or a combination thereof.
  • P2 is bound to A2 at or near an antigen binding site.In some embodiments, P2 has less than 70% sequence homology to the tumor antigen. In some embodiments, P2 comprises a peptide sequence of at least 10 amino acids in length. In some embodiments, P2 comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length. In some embodiments, P2 comprises a peptide sequence of at least 16 amino acids in length. In some embodiments, P2 comprises a peptide sequence of no more than 40 amino acids in length. In some embodiments, P2 comprises at least two cysteine amino acid residues. In some embodiments, P2 comprises a cyclic peptide or a linear peptide.
  • P2 comprises a cyclic peptide. In some embodiments, P2 comprises a linear peptide. In some embodiments, Li is bound to N-terminus of Ai. In some embodiments, Li is bound to C-terminus of Ai. In some embodiments, L2 is bound to N-terminus of A2. In some embodiments, L2 is bound to C-terminus of A2. In some embodiments, Li or L2 is a peptide sequence having at least 5 to no more than 50 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 10 to no more than 30 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 10 amino acids.
  • Li or L2 is a peptide sequence having at least 18 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 26 amino acids. In some embodiments, Li or I ⁇ has a formula comprising (G2S) n (SEQ ID NO: 922), wherein n is an integer from 1 to 3.
  • Li has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of at least 1.
  • Pi becomes unbound from Ai when Li is cleaved by the tumor specific protease thereby exposing Ai to CD3.
  • P2 becomes unbound from A2 when L2 is cleaved by the tumor specific protease thereby exposing A2 to the tumor antigen.
  • the tumor specific protease is selected from the group consisting of metalloprotease, serine protease, cysteine protease, threonine protease, and aspartic protease.
  • Li or L2 comprises a urokinase cleavable amino acid sequence, a matriptase cleavable amino acid sequence, a matrix metalloprotease cleavable amino acid sequence, or a legumain cleavable amino acid sequence.
  • Li or L2 comprises an amino acid sequence selected from the group consisting of GGGGSLSGRSDNHGSSGT (SEQ ID NO: 923), GGGGSSGGSGGSGLSGRSDNHGSSGT (SEQ ID NO: 924), ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), ISSGLLAGRSDNH (SEQ ID NO: 928), LSGRSDNH (SEQ ID NO: 929), ISSGLLSGRSDNP (SEQ ID NO: 930), ISSGLLSGRSDNH (SEQ ID NO: 931), LSGRSDNHSPLGLAGS (SEQ ID NO: 932), SPLGLAGSLSGRSDNH (SEQ ID NO: 933), SPLGLSGRSDNH (SEQ ID NO: 934), LAGRSDNHSPLGLAGS (SEQ ID NO: 935), LSGRSDNHVPLSLKMG (SEQ ID NO: 936), and LSGRSDNH (S
  • Li or L2 comprises an amino acid sequence selected from the group consisting of ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), and ISSGLLAGRSDNH (SEQ ID NO: 928).
  • compositions comprising (i) the polypeptides or polypeptide complexes of any one of the previous embodiments; and (ii) a pharmaceutically acceptable excipient.
  • Li a comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pi a to an anti-CD3 binding domain that binds to CD3 and; Pi a comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Li a is uncleaved wherein the peptide comprises an amino acid sequence according to Peptide-1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2; and Hi a comprises a half-life extending molecule.
  • Peptide-1 GSQCLGPEWEVCPY
  • Peptide-2 VYCGPEFDESVGCM
  • the peptide comprises the amino acid sequence of Peptide-1. In some embodiments, the peptide comprises the amino acid sequence of Peptide-2. In some embodiments, Hi a comprises a polymer. In some embodiments, the polymer is polyethylene glycol (PEG). In some embodiments, Hi a comprises albumin. In some embodiments, Hi a comprises an Fc domain. In some embodiments, the albumin is serum albumin. In some embodiments, the albumin is human serum albumin. In some embodiments, Hi a comprises a polypeptide, a ligand, or a small molecule.
  • the polypeptide, the ligand or the small molecule binds a serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • the serum protein is albumin.
  • the polypeptide is an antibody.
  • the antibody comprises a single domain antibody, a single chain variable fragment or a Fab.
  • the antibody comprises a single domain antibody that binds to albumin.
  • the antibody is a human or humanized antibody.
  • the single domain antibody is 645gHlgLl.
  • the single domain antibody is 645dsgH5gL4.
  • the single domain antibody is 23-13-A01 -sc02.
  • the single domain antibody is A10m3 or a fragment thereof.
  • the single domain antibody is DOM7r-31.
  • the single domain antibody is DOM7h-l 1-15.
  • the single domain antibody is Alb-1, Alb-8, or Alb-23. In some embodiments, the single domain antibody is 10G or 10GE. In some embodiments, the single domain antibody is SA21. In some embodiments, Hi a comprises a linking moiety (Lsa) that connects Hi a to Pi a . In some embodiments, L3 a is a peptide sequence having at least 5 to no more than 50 amino acids.
  • L3 a is a peptide sequence having at least 10 to no more than 30 amino acids. In some embodiments, L3 a is a peptide sequence having at least 10 amino acids. In some embodiments, L3 a is a peptide sequence having at least 18 amino acids. In some embodiments, L3 a is a peptide sequence having at least 26 amino acids. In some embodiments, L3 a has a formula selected from the group consisting of (G2S) n , (GS)n, (GSGGS)n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919). and (GSSGGS)n (SEQ ID NO: 920), wherein n is an integer of at least 1. In some embodiments, L3 a comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • FIG. 1A illustrates Peptide-1 peptide binding data to SP34. 185 scFv by ELISA.
  • Fig. IB illustrates Peptide-1 alanine scanning peptides binding data to SP34.185 scFv by ELISA.
  • Fig. 1C illustrates Peptide-1 alanine scanning peptides binding data to SP34.185 scFv by ELISA.
  • Fig. ID illustrates Peptide-2 peptide binding data to SP34. 185 scFv by ELISA.
  • Fig. IE illustrates Peptide-2 alanine scanning peptides binding data to SP34.185 scFv by ELISA.
  • Fig. IF illustrates Peptide-2 alanine scanning peptides binding data to SP34.185 scFv by ELISA.
  • Fig. 2A illustrates Peptide-1 inhibitory data of SP34.185 binding to CD3e.
  • Fig. 2B illustrates Peptide-1 alanine scanning peptides inhibitory data of SP34. 185 binding to CD3e.
  • Fig. 2C illustrates Peptide-1 alanine scanning peptides inhibitory data of SP34. 185 binding to CD3e.
  • Fig. 2D illustrates Peptide-2 inhibitory data of SP34.185 binding to CD3e.
  • Fig. 2E illustrates Peptide-2 alanine scanning peptides inhibitory data of SP34. 185 binding to CD3e.
  • Fig. 2F illustrates Peptide-2 alanine scanning peptides inhibitory data of SP34.185 binding to CD3e.
  • Fig. 3 illustrates titration data for CD3e binding for several polypeptide complexes of this disclosure.
  • Fig. 4 illustrates functional tumor cell killing of PC-1, PC-2, and PC-3.
  • Fig. 5A illustrates peptides (Peptide-29 - Peptide-34) peptide binding data to SP34.185 scFv by ELISA.
  • Peptide-2 is used as a positive control.
  • Fig. 5B illustrates peptides (Peptide-35 - Peptide-40) peptide binding data to SP34.185 scFv by ELISA.
  • Peptide-2 is used as a positive control.
  • Fig. 6A illustrates peptides (Peptide-29 - Peptide-34) inhibiting binding of SP34.185 scFv to CD3 by ELISA.
  • Peptide-2 is used as a positive control.
  • Fig. 6B illustrates peptides (Peptide-35 - Peptide-40) inhibiting binding of SP34. 185 scFv to CD3 by ELISA.
  • Peptide-2 is used as a positive control.
  • Fig. 7 illustrates the core sequence motif of Peptide-2 generated by WebLogo 3.
  • Protein-based therapies such as antibodies and bispecific or multispecific antibodies, such as T cell engagers, have proven effective for a variety diseases and disorders. As with any therapy, there is a need to minimize off-target effects of the protein-based therapy in healthy tissue while maintaining activity of the protein -based therapy in disease tissue.
  • One such strategy is to create an inactive form of the protein-based therapy in which a necessary binding site on the protein-based therapy is blocked with a peptide linked to the protein-based therapy, thereby preventing the protein-based therapy from binding or interacting with its cognate receptor or target antigen when in healthy tissue.
  • the peptide is linked to the protein-based therapy with a linker that is cleavable by a protease that is specific to the disease-state microenvironment.
  • the peptide is then released from the protein-based therapy when in the disease-state microenvironment.
  • peptides that impair binding of anti-CD3 binding domains to cluster of differentiation 3 (CD3).
  • the peptides as disclosed herein can be applied to a variety of antibody formats that bind to anti-CD3 to reduce the off-target effects of the antibodies in healthy tissue, while maintaining activity of the anti-CD3 antibody in a disease tissue.
  • the peptides are attached to the anti-CD3 binding domains via protease cleavable linkers.
  • the antibodies described herein are used in a method of treating cancer.
  • the cancer is a solid tumor cancer.
  • the cancer is lung, breast (e.g. HER2+; ER/PR+; TNBC), cervical, ovarian, colorectal, pancreatic or gastric.
  • isolated polypeptides or polypeptide complexes comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Peptide-1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2.
  • Peptide-1 GSQCLGPEWEVCPY
  • Peptide-2 VYCGPEFDESVGCM
  • isolated polypeptides or polypeptide complexes comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2 and 19-55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to an amino acid sequence selected from SEQ ID NOs: 1-2 and 19-55.
  • the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1- 2, and 19-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 1.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • Disclosed herein are isolated polypeptides or polypeptide complexes comprising an anti-CD3 binding domain that is linked to a peptide that impairs binding of the anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Z1-Z2-C- Z4-P-Z6-Z7 Z8- Z9-Z10-Z11- Z12- C-Z14 and Zi is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; Z2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; Z4 is selected from G and W; Ze is selected from E, D, V, and P; Z7 is selected from W, L, F,
  • Zg is selected from E, D, P, and Q;
  • Z9 is selected from E, D, Y, V, F, W, P, L, and Q;
  • Z is selected from S, D, Y, T, I, F, V, N, A, P, L, and H;
  • Zu is selected from I, Y, F, V, L, T, N, S, D, A, and H;
  • Z12 is selected from F, D, Y, L, I, V, A, N, T, P, S, and H;
  • Z14 is selected from D, Y, N, F, I, P, V, A, T, H, L and S.
  • Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Z is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Z12 is selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Zi is selected from D, Y, and F; Z2 is selected from D, Y, L, and F; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, and F; Zg is selected from E and D; Z9 is selected from E and D; Z10 is selected from S, D, and Y; Zu is selected from I, Y, and F; Z ⁇ is selected from F, D, Y, and L; and Z14 is selected from D, Y, and N.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • isolated polypeptides or polypeptide complexes comprising an anti-CD3 binding domain that is linked to a peptide that impairs binding of the anti-CD3 binding domain to CD3
  • the peptide comprises an amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8- U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P
  • U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S
  • U4 is selected from G and W
  • Ue is selected from E, D, V, and P
  • U7 is selected from
  • Ug is selected from E, D, P, and Q;
  • U9 is selected from E, D, Y, V, F, W, P, L, and Q;
  • U10 is selected from S, D, Y, T, I, F, V, N, A, P, L, and H;
  • Un is selected from I, Y, F, V, L, T, N, S, D, A, and H;
  • U12 is selected from F, D, Y, L, I, V, A, N, T, P, S, G, and H;
  • U14 is selected from D, Y, N, F, I, P, V, A, T, H, L, M, and S.
  • Ui is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; Us is selected from E and D; U7 is selected from W, L, F, G, and V; Ug is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; Un is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and U14 is selected from D, Y, N, F, I, M, and P.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • peptides that impairs binding of an anti- CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2.
  • peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to amino acid sequences of SEQ ID NOs: 1-2, and 19-55.
  • the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 1.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • peptide comprises an amino acid sequence according to Z1-Z2-C- Z4-P-Z6-Z7 Z8- Z9-Z10-Z11- Z12-C-Z14 and Zi is selected from D, Y, F, I, N, V, H, L, A, T, S, and P;
  • Z2 is selected from D, Y, L, F, I, N, A, V, H, T, and S;
  • Z4 is selected from G and W;
  • Ze is selected from E, D, V, and P;
  • Z7 is selected from W, L, F, V, G, M, I, and Y;
  • Zg is selected from E, D, P, and Q;
  • Z9 is selected from E, D, Y, V, F, W
  • Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Z is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Z12 is selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Zi is selected from D, Y, and F; Z2 is selected from D, Y, L, and F; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, and F; Zg is selected from E and D; Z9 is selected from E and D; Zw is selected from S, D, and Y; Zu is selected from I, Y, and F; Z12 is selected from F, D, Y, and L; and Z14 is selected from D, Y, and N.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • peptide comprises an amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8- U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P;
  • U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S;
  • U4 is selected from G and W;
  • Ue is selected from E, D, V, and P;
  • U7 is selected from W, L, F, V, G, M, I, and Y;
  • Ug is selected from E, D, P, and Q;
  • U9 is selected from E, D, Y, V,
  • Ui is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; Us is selected from E and D; U7 is selected from W, L, F, G, and V; Ug is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; Un is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and Uu is selected from D, Y, N, F, I, M, and P.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • the peptide is connected to the anti-CD3 binding domain in a configuration according to: A1-L1-P1 (Formula I) wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti- CD3 binding domain in a configuration according to: A1-L1-P1 (Formula I) wherein Ai is the anti-CD3 binding domain; Li is a cleavable linker that is a substrate for a tumor specific protease; Pi is the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti-CD3 binding domain in a configuration comprising Formula I: A1-L1-P1 (Formula I) wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Ai comprises the anti-CD3 binding domain
  • Li comprises a cleavable linker that is a substrate for a tumor specific protease
  • Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti-CD3 binding domain in a configuration comprising Formula I: A1-L1-P1 (Formula I) wherein Ai is the anti-CD3 binding domain; Li is a cleavable linker that is a substrate for a tumor specific protease; Piis the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Ai is further linked to a tumor antigen binding domain (A2).
  • the polypeptide or polypeptide complex is according to Formula la: P2-L2-A2-A1-L1-P1 (Formula la) wherein P2 comprises a peptide that impairs binding of A2 to a tumor antigen; and L2 comprises a second cleavable linker that connects A2to ?2and is a substrate for a tumor specific protease.
  • Pi is connected N-terminal to the cleavable linker and Ai is connected C- terminal to the cleavable linker. In some embodiments, Pi is connected C-terminal to the cleavable linker and Ai is connected N-terminal to the cleavable linker. In some embodiments, Pi is bound to Ai through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof.
  • Li a comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pi a to an anti-CD3 binding domain that binds to CD3 and; Pi a comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Li a is uncleaved wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, 19-55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to amino acid sequences of SEQ ID NOs: 1-2, 19- 55; and Hi a comprises a half-life extending molecule.
  • Pi a comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55. In some embodiments, Pi a comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, Pi a comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, Pi a comprises the amino acid sequence of SEQ ID NO: 54.
  • Lib- Pib-Hib wherein: Lib comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pib to an anti-CD3 binding domain that binds to CD3 and; Pib comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Lib is uncleaved wherein the peptide comprises the amino acid sequence according to Z1-Z2-C- Z4-P-Z6-Z7-Z8- Z9-Z10-Z11- Z12-C-Z14 and Zi is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; Z2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; Z4 is selected from G and W; Ze is selected from E, D, V, and P; Z7 is selected from W,
  • Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Zw is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Znis selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Pib comprises an amino acid sequence of Table 17.
  • Pib comprises an amino acid sequences according to any one of SEQ ID NOs: 44-55.
  • Pib comprises the amino acid sequences according to SEQ ID NO: 2.
  • Pib comprises the amino acid sequences according to SEQ ID NO: 54.
  • Li c comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pic to an anti-CD3 binding domain that binds to CD3 and; Pi c comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Lib is uncleaved wherein the peptide comprises the amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8- U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; Ue is selected from E, D, V, and P; U
  • Ui is selected from D, Y, F, I, V, and N;
  • U2 is selected from D, Y, L, F, I, and N;
  • U4 is selected from G and W;
  • Us is selected from E and D;
  • U7 is selected from W, L, F, G, and V;
  • Us is selected from E and D;
  • U9 is selected from E, D, Y, and V;
  • U10 is selected from S, D, Y, T, and I;
  • Un is selected from I, Y, F, V, L, and T;
  • U12 is selected from F, D, Y, L, I, V, A, G, and N;
  • U14 is selected from D, Y, N, F, I, M, and P.
  • Pi c comprises comprises an amino acid sequence of Table 17.
  • Pi c comprises an amino acid sequences according to any one of SEQ ID NOs: 44-55. In some embodiments, Pi c comprises the amino acid sequences according to SEQ ID NO: 2. In some embodiments, Pic comprises the amino acid sequences according to SEQ ID NO: 54.
  • the peptide (Pi, Pi a , Pib, orPi c ) comprises the amino acid sequence of Peptide- 1.
  • the peptide (Pi, Pi a , Pib, orPi c ) comprises the amino acid sequence of Peptide -2.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid substitution relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 2 amino acid substitution relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 3 amino acid substitution relative to Peptide- 1.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid substitution relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 2 amino acid substitutions relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 3 amino acid substitutions relative to Peptide-2.
  • the peptide (Pi, Pi ;i . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid deletion relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 2 amino acid deletions relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 3 amino acid deletions relative to Peptide- 1.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid deletions relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 2 amino acid deletions relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 3 amino acid deletions relative to Peptide-2.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid additions relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 2 amino acid additions relative to Peptide- 1. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 3 amino acid additions relative to Peptide- 1.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid addition relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 2 amino acid additions relative to Peptide-2. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 3 amino acid additions relative to Peptide-2.
  • the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 1 amino acid addition relative to Peptide-39. In some embodiments, the peptide (Pi, Pi a , Pib orPi c ) comprises an amino acid sequence that has 2 amino acid additions relative to Peptide-39. In some embodiments, the peptide (Pi, Pi a . Pib or Pi c ) comprises an amino acid sequence that has 3 amino acid additions relative to Peptide-39.
  • Pi is bound to Ai through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof.
  • Pi a is bound to the anti-CD3 binding domain through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof when Li a is uncleaved.
  • Pi, Pia, Pib or Pi c comprise a modified amino acid or non-natural amino acid, or a modified non-natural amino acid, or a combination thereof.
  • the modified amino acid or a modified non-natural amino acid comprises a post-translational modification.
  • Pi, Pi a ,Pib orPi c comprises a modification including, but not limited to acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation
  • Ai comprises an antibody or antibody fragment. In some embodiments, Ai comprises an antibody or antibody fragment that is human or humanized. In some embodiments, Li is bound to N-terminus of the antibody or antibody fragment of Ai. In some embodiments, A2 is bound to N-terminus of the antibody or antibody fragment of Ai. In some embodiments, Li is bound to the C-terminus of the antibody or antibody fragment of Ai. In some embodiments, A2 is bound to the C-terminus of the antibody or antibody fragment of Ai. In some embodiments, the antibody or antibody fragment comprises a single chain variable fragment, a single domain antibody, or a Fab fragment. In some embodiments, Ai is the single chain variable fragment (scFv).
  • the scFv comprises a scFv heavy chain polypeptide and a scFv light chain polypeptide.
  • Ai is the single domain antibody.
  • the antibody or antibody fragment thereof comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a camelid derived single domain antibody.
  • the first target antigen is CD3.
  • Ai comprises an anti- CD3e single chain variable fragment.
  • Ai comprises an anti-CD3e single chain variable fragment that has a KD binding of 1 pM or less to CD3 on CD3 expressing cells.
  • Ai comprises a variable light chain and variable heavy chain each of which is capable of specifically binding to human CD3.
  • Ai comprises complementary determining regions (CDRs) from sp34 scFv.
  • the scFv comprises a scFv heavy chain variable domain and an scFv light chain variable domain.
  • the polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease. In some embodiments, the polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease and Ai binds to the effector cell. In some embodiments, the effector cell is a T cell. In some embodiments, Ai binds to a polypeptide that is part of a TCR-CD3 complex on the effector cell. In some embodiments, the polypeptide that is part of the TCR-CD3 complex is human CD3s.
  • the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC- CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.
  • CDRs complementarity determining regions
  • the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC- CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.
  • CDRs complementarity determining regions
  • the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC- CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC- CDRI, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8.
  • CDRs complementarity determining regions
  • Ai comprises complementarity determining regions (CDRs): HC-CDR1, HC- CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of Ai comprise: HC- CDRI: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.
  • CDRs complementarity determining regions
  • Ai comprises complementarity determining regions (CDRs): LC-CDR1, LC- CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of Ai comprise: LC- CDRI: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.
  • CDRs complementarity determining regions
  • Ai comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of Ai comprise: HC- CDRI: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5; and Ai comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC- CDRI, the LC-CDR2, and the LC-CDR3 of Ai comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8.
  • CDRs complementarity determining regions
  • the scFv heavy chain variable domain comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 85% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 9.
  • the scFv heavy chain variable domain comprises an amino acid sequence that has at least 91% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 92% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 93% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 94% sequence identity to the amino acid sequence according to SEQ ID NO: 9.
  • the scFv heavy chain variable domain comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 9.
  • the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 50 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 60 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 60 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 70 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 70 consecutive amino acid residues of SEQ ID NO: 9.
  • the scFv heavy chain variable domain comprises an amino acid sequence of at least 80 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 80 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 90 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 90 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: v.
  • the scFv heavy chain variable domain comprises an amino acid sequence of at least 105 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 105 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 110 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 110 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 115 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 115 consecutive amino acid residues of SEQ ID NO: 9. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 120 consecutive amino acid residues of SEQ ID NO: 9, and has at least 95% sequence identity to the at least 120 consecutive amino acid residues of SEQ ID NO: 9.
  • A2 comprises an antibody or antibody fragment.
  • the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment, a single domain antibody, Fab’, or a Fab.
  • the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a camelid derived single domain antibody.
  • the antibody or antibody fragment thereof of A2 is humanized or human.
  • A2 is the Fab or Fab’.
  • the Fab or Fab’ comprises (a) a Fab light chain polypeptide and (b) a Fab heavy chain polypeptide.
  • the second target antigen comprises a tumor antigen.
  • the antibody or antibody fragment thereof comprises an epidermal growth factor receptor (EGFR) binding domain.
  • the antibody or antibody fragment thereof comprises a mesothelin binding domain.
  • A2 comprises an amino acid sequence disclosed in Table 3 or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to an amino acid sequence disclosed in Table 3). Table 3. Exemplary amino acid sequences of Anti-EGFR Fab
  • Pi is further linked to a half-life extending moiety (Hi).
  • the half-life extending moiety is a single-domain antibody.
  • Hi does not block Pi binding to CD3. In some embodiments, Hi a does not block the anti-CD3 binding domain from binding to the CD3. In some embodiments, Hib does not block the anti-CD3 binding domain from binding to the CD3. In some embodiments, Hi c does not block the anti-CD3 binding domain from binding to the CD3. In some embodiments, the half-life extending molecule (Hi, H i ;i . Hib, or Hi c ) does not have binding affinity to CD3. In some embodiments, the half-life extending molecule (Hi, Hi a , Hib, or Hi c ) does not have binding affinity to CD3. In some embodiments, the half-life extending molecule (Hi, Hi a , Hib, or Hi c ) does not shield the anti-CD3 binding domain from CD3.
  • Hi, Hia, Hib, or Hi c comprise an amino acid sequence that has repetitive sequence motifs. In some embodiments, Hi, Hi a , Hib, or Hi c comprises an amino acid sequence that has highly ordered secondary structure. “Highly ordered secondary structure,” as used in this context, means that at least about 50%, or about 70%, or about 80%, or about 90%, of amino acid residues of Hi or Hi a contribute to secondary structure, as measured or determined by means, including, but not limited to, spectrophotometry (e.g.
  • Hi, Hia, Hib, or Hi c comprises a polymer.
  • the polymer is polyethylene glycol (PEG).
  • Hi or Hi a comprises albumin.
  • Hi or Hi a comprises a Fc domain.
  • the albumin is serum albumin.
  • the albumin is human serum albumin.
  • Hi,Hi a ,Hib,or Hi c comprises a polypeptide, a ligand, or a small molecule.
  • the polypeptide, the ligand or the small molecule binds serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • the serum protein is albumin.
  • the polypeptide is an antibody.
  • the antibody comprises a single domain antibody, a single chain variable fragment or a Fab. In some embodiments, the antibody comprises a single domain antibody.
  • the antibody comprises a single domain antibody that binds to albumin. In some embodiments, the antibody comprises a single domain antibody that binds to human serum albumin. In some embodiments, the antibody is a human or humanized antibody. In some embodiments, the antibody is selected from the group consisting of 645gHlgLl, 645dsgH5gL4, 23-I3-A0I -sc02, AI0m3 or a fragment thereof, DOM7r-31, DOM7h-ll-15, Alb-1, Alb-8, Alb-23, 10G, 10GE, and SA21.
  • Hi comprises a single domain antibody. In some embodiments, Hi comprises a single domain antibody that binds to albumin. In some embodiments, Hi comprises a single domain antibody that binds to human serum albumin. In some embodiments, Hi a comprises a single domain antibody. In some embodiments, Hi a comprises a single domain antibody that binds to albumin. In some embodiments, Hi a comprises a single domain antibody that binds to human serum albumin. In some embodiments, Hib comprises a single domain antibody. In some embodiments, Hib comprises a single domain antibody that binds to albumin. In some embodiments, Hib comprises a single domain antibody that binds to human serum albumin. In some embodiments, Hi c comprises a single domain antibody. In some embodiments, Hi c comprises a single domain antibody that binds to albumin. In some embodiments, Hi c comprises a single domain antibody that binds to human serum albumin.
  • Hi, Hia, Hib, or Hi c comprise a modified amino acid or non-natural amino acid, or a modified non-natural amino acid, or a combination thereof.
  • the modified amino acid or a modified non-natural amino acid comprises a post-translational modification.
  • Hi, Hi a , Hib, or Hi c comprise a modification including, but not limited to acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation,
  • Hi, H i a . Hib, or Hi c including the peptide backbone, the amino acid side chains, and the terminus.
  • Hi, HI ;I . Hib, or Hi c comprises an amino acid sequence disclosed in Table 4 or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to an amino acid sequence disclosed in Table 4).
  • P2 impairs binding of A2to the tumor antigen.
  • P2 is bound to A2 through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof.
  • P2 is bound to A2 at or near an antigen binding site.
  • P2 has less than 70% sequence homology to the tumor antigen.
  • P2 has less than 75% sequence homology to the tumor antigen.
  • P2 has less than 80% sequence homology to the tumor antigen.
  • P2 has less than 85% sequence homology to the tumor antigen.
  • P2 has less than 90% sequence homology to the tumor antigen. In some embodiments, P2 has less than 95% sequence homology to the tumor antigen. In some embodiments, P2 has less than 98% sequence homology to the tumor antigen. In some embodiments, P2 has less than 99% sequence homology to the tumor antigen.
  • P2 comprises a peptide sequence of at least 10 amino acids in length. In some embodiments, P2 comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length. In some embodiments, P2 comprises a peptide sequence of at least 16 amino acids in length. In some embodiments, P2 comprises a peptide sequence of no more than 40 amino acids in length. In some embodiments, P2 comprises at least two cysteine amino acid residues. In some embodiments, P2 comprises a cyclic peptide or a linear peptide. In some embodiments, P2 comprises a cyclic peptide.In some embodiments, P2 comprises a linear peptide.
  • P2 comprise a modified amino acid or non-natural amino acid, or a modified non-natural amino acid, or a combination thereof.
  • the modified amino acid or a modified non-natural amino acid comprises a post-translational modification.
  • P2 comprise a modification including, but not limited to acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Modifications are made
  • P2 does not comprise albumin or an albumin fragment. In some embodiments, P2 does not comprise an albumin binding domain.
  • Li or L2 is a peptide sequence having at least 5 to no more than 50 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 10 to no more than 30 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 10 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 18 amino acids. In some embodiments, Li or L2 is a peptide sequence having at least 26 amino acids.
  • Li has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS)n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919), and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of at least 1.
  • Li has a formula selected from the group consisting of (G 2 S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS)n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of 1.
  • Li has a formula selected from the group consisting of (G2S) n (SEQ ID NO: 922), (GS) n (SEQ ID NO: 938), (GSGGS) n (SEQ ID NO: 939), (GGGS) n (SEQ ID NO: 940), (GGGGS) n (SEQ ID NO: 941), and (GSSGGS)n (SEQ ID NO: 942), wherein n is an integer from 1 to 3.
  • Li has a formula of (G2S)n, wherein n is an integer of least 1. In some embodiments, Li has a formula of (GS) n , wherein n is an integer of least 1. In some embodiments, Li has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of least 1. In some embodiments, Li has a formula of (GGGS) n (SEQ ID NO: 918),, wherein n is an integer of least 1. In some embodiments, Li has a formula of (GGGGS) n (SEQ ID NO: 919),, wherein n is an integer of least 1. In some embodiments, Li has a formula of (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of least 1.
  • Li has a formula of (G2S)n, wherein n is an integer of 1. In some embodiments, Li has a formula of (GS) n , wherein n is an integer of 1. In some embodiments, Li has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of 1. In some embodiments, Li has a formula of (GGGS) n (SEQ ID NO: 918),, wherein n is an integer of 1. In some embodiments, Li has a formula of (GGGGS) n (SEQ ID NO: 919),, wherein n is an integer of 1. In some embodiments, Li has a formula of (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of 1.
  • Li has a formula of (G2S) n (SEQ ID NO: 922), wherein n is an integer from 1 to 3.
  • Li has a formula of (GS) n (SEQ ID NO: 938), wherein n is an integer from 1 to 3.
  • Li has a formula of (GSGGS) n (SEQ ID NO: 939), wherein n is an integer from 1 to 3.
  • Li has a formula of (GGGS) n (SEQ ID NO: 940),, wherein n is an integer from 1 to 3.
  • Li has a formula of (GGGGS) n (SEQ ID NO: 941), wherein n is an integer from 1 to 3. In some embodiments, Li has a formula of (GSSGGS) n (SEQ ID NO: 942), wherein n is an integer from 1 to 3.
  • Li is a substrate for a tumor specific protease.
  • the tumor specific protease is selected from the group consisting of metalloprotease, serine protease, cysteine protease, threonine protease, and aspartic protease.
  • Li comprises a urokinase cleavable amino acid sequence, a matriptase cleavable amino acid sequence, a matrix metalloprotease cleavable amino acid sequence, or a legumain cleavable amino acid sequence.
  • Li comprises an amino acid sequence selected from the group consisting of GGGGSLSGRSDNHGSSGT (SEQ ID NO: 923), GGGGSSGGSGGSGLSGRSDNHGSSGT (SEQ ID NO: 924), ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), ISSGLLAGRSDNH (SEQ ID NO: 928), LSGRSDNH (SEQ ID NO: 929), ISSGLLSGRSDNP (SEQ ID NO: 930), ISSGLLSGRSDNH (SEQ ID NO: 931), LSGRSDNHSPLGLAGS (SEQ ID NO: 932), SPLGLAGSLSGRSDNH (SEQ ID NO: 933), SPLGLSGRSDNH (SEQ ID NO: 934), LAGRSDNHSPLGLAGS (SEQ ID NO: 935), LSGRSDNHVPLSLKMG (SEQ ID NO: 936), and LSGRSDNHVP
  • Li comprises an amino acid sequence selected from the group consisting of ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), and ISSGLLAGRSDNH (SEQ ID NO: 928).
  • L2 has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS)n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919), and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of at least 1.
  • L2 has a formula selected from the group consisting of (G 2 S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS)n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of 1.
  • L2 has a formula selected from the group consisting of (G2S) n (SEQ ID NO: 922), (GS) n (SEQ ID NO: 938), (GSGGS) n (SEQ ID NO: 939), (GGGS) n (SEQ ID NO: 940), (GGGGS) n (SEQ ID NO: 941), and (GSSGGS)n (SEQ ID NO: 942), wherein n is an integer from 1 to 3.
  • L2 has a formula of (G2S)n, wherein n is an integer of least 1. In some embodiments, L2 has a formula of (GS) n , wherein n is an integer of least 1. In some embodiments, L2 has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of least 1. In some embodiments, L2 has a formula of (GGGS) n (SEQ ID NO: 918),, wherein n is an integer of least 1. In some embodiments, L2 has a formula of (GGGGS) n (SEQ ID NO: 919),, wherein n is an integer of least 1. In some embodiments, L2 has a formula of (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of least 1.
  • L2 has a formula of (G2S)n, wherein n is an integer of 1. In some embodiments, L2 has a formula of (GS) n , wherein n is an integer of 1. In some embodiments, L2 has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of 1. In some embodiments, L2 has a formula of (GGGS) n (SEQ ID NO: 918),, wherein n is an integer of 1. In some embodiments, L2 has a formula of (GGGGS) n (SEQ ID NO: 919),, wherein n is an integer of 1.
  • L2 has a formula of (GSSGGS) n (SEQ ID NO: 920), wherein n is an integer of 1. [0085] In some embodiments, L2 has a formula of (G2S) n (SEQ ID NO: 922), wherein n is an integer from 1 to 3. In some embodiments, L2 has a formula of (GS) n (SEQ ID NO: 938), wherein n is an integer from 1 to 3. In some embodiments, L2 has a formula of (GSGGS) n (SEQ ID NO: 939), wherein n is an integer from 1 to 3. In some embodiments, L2 has a formula of (GGGS) n (SEQ ID NO: 940).
  • L2 has a formula of (GGGGS) n (SEQ ID NO: 941 ). wherein n is an integer from 1 to 3. In some embodiments, L2 has a formula of (GSSGGS) n (SEQ ID NO: 942), wherein n is an integer from 1 to 3.
  • L2 is a substrate for a tumor specific protease.
  • the tumor specific protease is selected from the group consisting of metalloprotease, serine protease, cysteine protease, threonine protease, and aspartic protease.
  • L2 comprises a urokinase cleavable amino acid sequence, a matriptase cleavable amino acid sequence, a matrix metalloprotease cleavable amino acid sequence, or a legumain cleavable amino acid sequence.
  • L2 comprises an amino acid sequence selected from the group consisting of GGGGSLSGRSDNHGSSGT (SEQ ID NO: 923), GGGGSSGGSGGSGLSGRSDNHGSSGT (SEQ ID NO: 924), ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), ISSGLLAGRSDNH (SEQ ID NO: 928), LSGRSDNH (SEQ ID NO: 929), ISSGLLSGRSDNP (SEQ ID NO: 930), ISSGLLSGRSDNH (SEQ ID NO: 931), LSGRSDNHSPLGLAGS (SEQ ID NO: 932), SPLGLAGSLSGRSDNH (SEQ ID NO: 933), SPLGLSGRSDNH (SEQ ID NO: 934), LAGRSDNHSPLGLAGS (SEQ ID NO: 935), LSGRSDNHVPLSLKMG (SEQ ID NO: 936), and LSGRSDNH
  • L2 comprises an amino acid sequence selected from the group consisting of ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), ISSGLLAGRSDNH (SEQ ID NO: 928), or GGGGSGGGSGGISSGLLSGRSDNHGGGS (SEQ ID NO: 943).
  • Li or L2 comprises a modified amino acid or non-natural amino acid, or a modified non-natural amino acid, or a combination thereof.
  • the modified amino acid or a modified non-natural amino acid comprises a post-translational modification.
  • Li or L2 comprises a modification including, but not limited, to acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
  • Hi comprises a linking moiety (L3) that connects Hi to Pi.
  • Hi a comprises a linking moiety (Lsa) that connects Hi a to Pi a .
  • Hib comprises a linking moiety (L31,) that connects Hu, to Pit,.
  • Hib comprises a linking moiety (L; c ) that connects Hi c to Pi c .
  • L3, L33, L3b, or L3C is a peptide sequence having at least 5 to no more than 50 amino acids. In some embodiments, L3, L33, L3b, or L3C is a peptide sequence having at least 10 to no more than 30 amino acids. In some embodiments, L3, L33. L3b. or L3C is a peptide sequence having at least 10 amino acids. In some embodiments, L3, L33. L3b.or L3 C is a peptide sequence having at least 18 amino acids. In some embodiments, L3, L33, L3b, or L3C is a peptide sequence having at least 26 amino acids.
  • L3, L3 a , L3b, or L3C has a formula selected from the group consisting of (G2S) n , (GS)n, (GSGGS)n (SEQ ID NO: 917), (GGGS) n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919). and (GSSGGS)n (SEQ ID NO: 920). wherein n is an integer of at least 1.
  • L3, L3 a ,L3b, or L3C has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918). (GGGGS) n (SEQ ID NO: 919).and (GSSGGS) n (SEQ ID NO: 920). wherein n is an integer of 1.
  • L3, L33, L3b, or L3C has a formula selected from the group consisting of (G 2 S)n (SEQ ID NO: 922), (GS) n (SEQ ID NO: 938), (GSGGS) n (SEQ ID NO: 939), (GGGS) n (SEQ ID NO: 940). (GGGGS)n (SEQ ID NO: 941).and (GSSGGS) n (SEQ ID NO: 942). wherein n is an integer from 1 to 3.
  • L3, L3 a , L3b, or L3C has a formula of (G2S)n, wherein n is an integer of least 1. In some embodiments, L3, L3 a , L3b, or L3C has a formula of (GS) n , wherein n is an integer of least 1. In some embodiments, L3, L33. L3b.or L3C has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of least 1. In some embodiments, L3, L3 a , L3b, or L3C has a formula of (GGGS) n (SEQ ID NO: 918).. wherein n is an integer of least 1.
  • L3, L3 a ,L3b,or L3C has a formula of (GGGGS) n (SEQ ID NO: 919). wherein n is an integer of least 1. In some embodiments, L3, L3 a , L3b, or L3C has a formula of (GSSGGS)n (SEQ ID NO: 920). wherein n is an integer of least 1.
  • L3 or L3 a has a formula of (G2S) n , wherein n is an integer of 1.
  • L3, L33, L3b, or L3C has a formula of (GS) n , wherein n is an integer of 1.
  • L3, L 3a , L3b, or L3C has a formula of (GSGGS) n (SEQ ID NO: 917), wherein n is an integer of 1.
  • L3, L33. L3b.or L3C has a formula of (GGGS) n (SEQ ID NO: 918).. wherein n is an integer of 1.
  • L3, L33, L3b, or L3C has a formula of (GGGGS) n (SEQ ID NO: 919).. wherein n is an integer of 1. In some embodiments, L3, L3 a ,L3b, or L3C has a formula of (GSSGGS) n (SEQ ID NO: 920). wherein n is an integer of 1.
  • L3, L33, L3b, or L3C has a formula of (G2S) n (SEQ ID NO: 922). wherein n is an integer from 1 to 3.
  • L3, L33. L3b.or L3C has a formula of (GS) n (SEQ ID NO: 938), wherein n is an integer from 1 to 3.
  • L3, L33, L3b, or L3C has a formula of (GSGGS) n (SEQ ID NO: 939), wherein n is an integer from 1 to 3.
  • L3, L33, L3b, or L3C has a formula of (GGGS) n (SEQ ID NO: 940).
  • L3, L33, Lsb, or Lsc has a formula of (GGGGS) n (SEQ ID NO: 941),, wherein n is an integer from 1 to 3.
  • L3, L3a, L3b,or L3C has a formula of (GSSGGS) n (SEQ ID NO: 942), wherein n is an integer from 1 to 3.
  • the Fab light chain polypeptide of A2 is bound to a C-terminus of the single chain variable fragment (scFv) of Ai. In some embodiments, the Fab heavy chain polypeptide of A2 is bound to a C-terminus of the single chain variable fragment (scFv) Ai. In some embodiments, the Fab light chain polypeptide of A2 is bound to a N-terminus of the single chain variable fragment (scFv) of Ai. In some embodiments, the Fab heavy chain polypeptide of A2 is bound to a N-terminus of the single chain variable fragment (scFv) Ai.
  • the Fab heavy chain polypeptide of A2 is bound to the scFv heavy chain polypeptide of Ai. In some embodiments, the Fab light chain polypeptide of A2 is bound to the scFv heavy chain polypeptide of Ai. In some embodiments, the Fab heavy chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai. In some embodiments, the Fab light chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai. In some embodiments, the Fab heavy chain polypeptide of A2 is bound to the scFv heavy chain polypeptide of Ai and L2 is bound to the Fab light chain polypeptide of A 2 .
  • the Fab light chain polypeptide of A2 is bound to the scFv heavy chain polypeptide of Ai and L2 is bound to the Fab heavy chain polypeptide of A2. In some embodiments, the Fab heavy chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab light chain polypeptide of A2. In some embodiments, the Fab light chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab heavy chain polypeptide of A2.
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 1 :
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide (Pi) wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein Pi impairs binding of the scFv to CD3 and Pi is linked to a N- terminus of the light chain variable domain of the scFv with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 2:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein the peptide impairs binding of the scFv to CD3 and the peptide is linked to the light chain variable domain of the scFv with a linking moiety that is a substrate for a tumor specific protease, and the peptide is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen, wherein the Fab
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 3:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide (Pi) wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein Pi impairs binding of the scFv to CD3 and Pi is linked to a N- terminus of the light chain variable domain of the scFv with a linking moiety that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen, wherein the
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 4:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is further linked to a peptide wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein the peptide impairs binding of the scFv to CD3 and the peptide is linked to a N-terminus of the light chain variable domain of the scFv with a linking moiety that is a substrate for a tumor specific protease, and the peptide is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 5:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide (Pi) wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein Pi impairs binding of the scFv to CD3 and Pi is linked to a N- terminus of the heavy chain variable domain of the scFv with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 6:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein the peptide impairs binding of the scFv to CD3 and the peptide is linked to the heavy chain variable domain of the scFv with a linking moiety that is a substrate for a tumor specific protease, and the peptide is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen, wherein the Fab
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 7:
  • the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide (Pi) wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide- 1 or Peptide-2, wherein Pi impairs binding of the scFv to CD3 and Pi is linked to a N- terminus of the heavy chain variable domain of the scFv with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a Fab that binds to a tumor cell antigen
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 8: wherein the polypeptide or polypeptide complex comprises a single chain variable fragment (scFv) comprising a light chain variable domain and a heavy chain variable domain, wherein the scFv is linked to a peptide wherein the peptide comprises an amino acid sequence according to Peptide-1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2, wherein the peptide impairs binding of the scFv to CD3 and the peptide is linked to a N-terminus of the heavy chain variable domain of the scFv with a linking moiety that is a substrate for a tumor specific protease,
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 9:
  • the polypeptide or polypeptide complex comprises a Fab that binds to a tumor cell antigen, the Fab comprising a Fab light chain polypeptide and a Fab heavy chain polypeptide, wherein the Fab is linked to a peptide (Pi) that impairs binding of the Fab to the tumor cell antigen and Pi is linked to a N terminus of the Fab light chain polypeptide with a linking moiety (Li) that is a substrate for a tumor specific protease, and the Pi is further linked to a half-life extending molecule; and a single chain variable fragment (scFv) that binds to an effector cell antigen, the scFv comprising a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain of the scFv is linked to an N terminus of the Fab heavy chain polypeptide, wherein the scFv is linked to P2 and L2, wherein P2 comprises a peptide according to
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 10:
  • the polypeptide or polypeptide complex comprises a Fab that binds to a tumor cell antigen, the Fab comprising a Fab light chain polypeptide and a Fab heavy chain polypeptide, wherein the Fab is linked to a peptide (Pi) that impairs binding of the Fab to the tumor cell antigen and Pi is linked to a N terminus of the Fab heavy chain polypeptide with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a single chain variable fragment (scFv) that binds to an effector cell antigen, the scFv comprising a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain of the scFv is linked to an N terminus of the Fab light chain polypeptide, wherein the scFv further is linked to P2 and L2, wherein P2 comprises a peptide according to
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 11 :
  • the polypeptide or polypeptide complex comprises a Fab that binds to a tumor cell antigen, the Fab comprising a Fab light chain polypeptide and a Fab heavy chain polypeptide, wherein the Fab is linked to a peptide (Pi) that impairs binding of the Fab to the tumor cell antigen and Pi is linked to a N terminus of the Fab light chain polypeptide with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a single chain variable fragment (scFv) that binds to an effector cell antigen, the scFv comprising a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain of the scFv is linked to an N terminus of the Fab heavy chain polypeptide, wherein the scFv is linked to P2 and L2, wherein P2 comprises a peptide according to an
  • polypeptides or polypeptide complexes comprising a structural arrangement according to Configuration 12:
  • the polypeptide or polypeptide complex comprises a Fab that binds to a tumor cell antigen, the Fab comprising a Fab light chain polypeptide and a Fab heavy chain polypeptide, wherein the Fab is linked to a (Pi) that impairs binding of the Fab to the tumor cell antigen and Pi is linked to a N terminus of the Fab heavy chain polypeptide with a linking moiety (Li) that is a substrate for a tumor specific protease, and Pi is further linked to a half-life extending molecule; and a single chain variable fragment (scFv) that binds to an effector cell antigen, the scFv comprising a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain of the scFv is linked to an N terminus of the Fab light chain polypeptide, wherein the scFv is linked to P2 and L2, wherein P2 comprises a peptide according to an amino acid sequence
  • Polypeptides or polypeptide complexes in some embodiments, comprise a sequence set forth in Table 5.
  • the sequence comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 13-18.
  • polypeptides or polypeptide complexes as disclosed herein.
  • the polypeptides or polypeptide complexes comprise an antibody or an antibody fragment.
  • isolated recombinant nucleic acid molecules encoding polypeptide or polypeptide complex comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Peptide- 1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2, or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to the amino acid sequence of Peptide-1 or Peptide-2.
  • GSQCLGPEWEVCPY SEQ ID NO: 1
  • Peptide-2 VYCGPEFDESVGCM
  • isolated recombinant nucleic acid molecules encoding polypeptide or polypeptide complex comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Peptide-1 (GSQCLGPEWEVCPY) SEQ ID NO: 1 or Peptide-2 (VYCGPEFDESVGCM) SEQ ID NO: 2.
  • isolated recombinant nucleic acid molecules encoding polypeptides or polypeptide complexes comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, 19- 55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to an amino acid sequence selected from SEQ ID NOs: 1-2, 19-55.
  • the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 1.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Z10 is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Z12 is selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Zi is selected from D, Y, and F; Z2 is selected from D, Y, L, and F; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, and F; Zg is selected from E and D; Z9 is selected from E and D; Z10 is selected from S, D, and Y; Zu is selected from I, Y, and F; Z12 is selected from F, D, Y, and L; and Z14 is selected from D, Y, and N.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • nucleic acid molecules encoding polypeptides or polypeptide complexes comprising an anti-CD3 binding domain that is linked to a peptide that impairs binding of the anti-CD3 binding domain to CD3
  • the peptide comprises an amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8- U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P;
  • U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S;
  • U4 is selected from G and W;
  • Ue is selected from E, D, V, and P;
  • U7 is selected from W, L, F, V, G, M, I, and Y;
  • Ug is selected from E, D, P, and Q;
  • U9 is selected from E, D, D, P, and Q;
  • Ui is selected from D, Y, F, I, V, and N;
  • U2 is selected from D, Y, L, F, I, and N;
  • U4 is selected from G and W;
  • Ue is selected from E and D;
  • U7 is selected from W, L, F, G, and V;
  • Ug is selected from E and D;
  • U9 is selected from E, D, Y, and V;
  • U10 is selected from S, D, Y, T, and I;
  • Un is selected from I, Y, F, V, L, and T;
  • U12 is selected from F, D, Y, L, I, V, A, G, and N;
  • U14 is selected from D, Y, N, F, I, M, and P.
  • the peptide comprises an amino acid sequence of Table 17.
  • the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • the peptide is connected to the anti-CD3 binding domain in a configuration according to: Ai-Li-Pi (Formula I) wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti- CD3 binding domain in a configuration according to: Ai-Li-P (Formula I) wherein Ai is the anti-CD3 binding domain; Li is a cleavable linker that is a substrate for a tumor specific protease; Pi is the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti-CD3 binding domain in a configuration comprising Formula I: Ai-Li-Pi (Formula I) wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Ai comprises the anti-CD3 binding domain
  • Li comprises a cleavable linker that is a substrate for a tumor specific protease
  • Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • the peptide is connected to the anti-CD3 binding domain in a configuration comprising Formula I: Ai-Li-Pi (Formula I) wherein Ai is the anti-CD3 binding domain; Li is a cleavable linker that is a substrate for a tumor specific protease; Piis the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Ai is further linked to a tumor antigen binding domain (A2).
  • the polypeptide or polypeptide complex is according to Formula la: P2-L2-A2-A1-L1-P1 (Formula la) wherein P2 comprises a peptide that impairs binding of A2to a tumor antigen; and L2 comprises a second cleavable linker that connects A2 to P2 and is a substrate for a tumor specific protease .
  • compositions comprising: (a) the polypeptides or polypeptide complexes as disclosed herein; and (b) a pharmaceutically acceptable excipient.
  • the polypeptide or polypeptide complex further comprises a detectable label, a therapeutic agent, or a pharmacokinetic modifying moiety.
  • the detectable label comprises a fluorescent label, a radiolabel, an enzyme, a nucleic acid probe, or a contrast agent.
  • the polypeptide or polypeptide complex as disclosed herein may be provided in a pharmaceutical composition together with one or more pharmaceutically acceptable carriers or excipients.
  • pharmaceutically acceptable carrier includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered.
  • suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
  • Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose.
  • the compositions are sterile. These compositions may also contain adjuvants such as preservative, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents.
  • the pharmaceutical composition may be in any suitable form, (depending upon the desired method of administration). It may be provided in unit dosage form, may be provided in a sealed container and may be provided as part of a kit. Such a kit may include instructions for use. It may include a plurality of said unit dosage forms.
  • compositions may be adapted for administration by any appropriate route, including a parenteral (e.g., subcutaneous, intramuscular, or intravenous) route.
  • parenteral e.g., subcutaneous, intramuscular, or intravenous
  • Such compositions may be prepared by any method known in the art of pharmacy, for example by mixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.
  • Dosages of the substances of the present disclosure can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used.
  • polypeptides described herein are produced using any method known in the art to be useful for the synthesis of polypeptides (e.g., antibodies), in particular, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression techniques.
  • an antibody or its binding fragment thereof is expressed recombinantly, and the nucleic acid encoding the antibody or its binding fragment is assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.
  • chemically synthesized oligonucleotides e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242
  • a nucleic acid molecule encoding an antibody is optionally generated from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.
  • a suitable source e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin
  • an antibody or its binding is optionally generated by immunizing an animal, such as a mouse, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, Nature 256:495-497) or, as described by Kozbor et al. (1983, Immunology Today 4:72) or Cole et al. (1985 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • a clone encoding at least the Fab portion of the antibody is optionally obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, Science 246: 1275-1281) for clones of Fab fragments that bind the specific antigen or by screening antibody libraries (See, e.g., Clackson et al., 1991, Nature 352:624; Hane et al., 1997 Proc. Natl. Acad. Sci. USA 94:4937).
  • chimeric antibodies techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity are used.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.
  • single chain antibodies are adapted to produce single chain antibodies.
  • Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
  • Techniques for the assembly of functional Fv fragments in E. coli are also optionally used (Skerra et al., 1988, Science 242: 1038-1041).
  • an expression vector comprising the nucleotide sequence of an antibody or the nucleotide sequence of an antibody is transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation), and the transfected cells are then cultured by conventional techniques to produce the antibody.
  • the expression of the antibody is regulated by a constitutive, an inducible or a tissue, specific promoter.
  • host-expression vector systems is utilized to express an antibody, or its binding fragment described herein.
  • host-expression systems represent vehicles by which the coding sequences of the antibody is produced and subsequently purified, but also represent cells that are, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody or its binding fragment in situ.
  • host-expression systems represent vehicles by which the coding sequences of the antibody is produced and subsequently purified, but also represent cells that are, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody or its binding fragment in situ.
  • microorganisms such as bacteria (e.g., E. coli and B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing an antibody or its binding fragment coding sequences; yeast (e.g., Saccharomyces Pichia) transformed with recombinant yeast expression vectors containing an antibody or its binding fragment coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing an antibody or its binding fragment coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing an antibody or its binding fragment coding sequences; or mammalian cell systems (e.g., COS, CHO, BH, 293, 293T, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the
  • cell lines that stably express an antibody are optionally engineered.
  • host cells are transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
  • appropriate expression control elements e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.
  • engineered cells are then allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn are cloned and expanded into cell lines.
  • This method can advantageously be used to engineer cell lines which express the antibody or its binding fragments.
  • a number of selection systems are used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 192, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes are employed in tk-, hgprt- or aprt- cells, respectively.
  • antimetabolite resistance are used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci.
  • the expression levels of an antibody are increased by vector amplification (for a review, see Bebbington and Hentschel, the use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)).
  • vector amplification for a review, see Bebbington and Hentschel, the use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)
  • a marker in the vector system expressing an antibody is amplifiable
  • an increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell Biol. 3:257).
  • any method known in the art for purification of an antibody is used, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography
  • centrifugation e.g., centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • vectors include any suitable vectors derived from either a eukaryotic or prokaryotic sources.
  • vectors are obtained from bacteria (e.g. E. coli), insects, yeast (e.g. Pichia pastoris), algae, or mammalian sources.
  • Exemplary bacterial vectors include pACYC177, pASK75, pBAD vector series, pBADM vector series, pET vector series, pETM vector series, pGEX vector series, pHAT, pHAT2, pMal-c2, pMal-p2, pQE vector series, pRSET A, pRSET B, pRSET C, pTrcHis2 series, pZA31-Luc, pZE21-MCS-l, pFLAG ATS, pFLAG CTS, pFLAG MAC, pFLAG Shift-12c, pTAC-MAT-1, pFLAG CTC, or pTAC-MAT-2.
  • Exemplary insect vectors include pFastBacl, pFastBac DUAL, pFastBac ET, pFastBac HTa, pFastBac HTb, pFastBac HTc, pFastBac M30a, pFastBact M30b, pFastBac, M30c, pVL1392, pVL1393, pVL1393 M10, pVL1393 Mi l, pVL1393 Ml 2, FLAG vectors such as pPolh-FLAGl or pPolh-MAT 2, or MAT vectors such as pPolh-MATl, or pPolh-MAT2.
  • yeast vectors include Gateway® pDESTTM 14 vector, Gateway® pDESTTM 15 vector, Gateway® pDESTTM 17 vector, Gateway® pDESTTM 24 vector, Gateway® pYES-DEST52 vector, pBAD- DEST49 Gateway® destination vector, pAO815 Pichia vector, pFLDl Pichi pastoris vector, pGAPZA,B, & C Pichia pastoris vector, pPIC3.5K Pichia vector, pPIC6 A, B, & C Pichia vector, pPIC9K Pichia vector, pTEFl/Zeo, pYES2 yeast vector, pYES2/CT yeast vector, pYES2/NT A, B, & C yeast vector, or pYES3/CT yeast vector.
  • Exemplary algae vectors include pChlamy-4 vector or MCS vector.
  • mammalian vectors include transient expression vectors or stable expression vectors.
  • Mammalian transient expression vectors may include pRK5, p3xFLAG-CMV 8, pFLAG-Myc-CMV 19, pFLAG- Myc-CMV 23, pFLAG-CMV 2, pFLAG-CMV 6a,b,c, pFLAG-CMV 5.1, pFLAG-CMV 5a,b,c, p3xFLAG-CMV 7.1, pFLAG-CMV 20, p3xFLAG-Myc-CMV 24, pCMV-FLAG-MATl, pCMV-FLAG-MAT2, pBICEP-CMV 3, or pBICEP-CMV 4.
  • Mammalian stable expression vector may include pFLAG-CMV 3, p3xFLAG-CMV 9, p3xFLAG-CMV 13, pFLAG-Myc-CMV 21, p3xFLAG-Myc-CMV 25, pFLAG-CMV 4, p3xFLAG-CMV 10, p3xFLAG-CMV 14, pFLAG-Myc-CMV 22, p3xFLAG-Myc-CMV 26, pBICEP-CMV 1, or pBICEP-CMV 2.
  • a cell-free system is a mixture of cytoplasmic and/or nuclear components from a cell and is used for in vitro nucleic acid synthesis.
  • a cell-free system utilizes either prokaryotic cell components or eukaryotic cell components.
  • a nucleic acid synthesis is obtained in a cell-free system based on for example Drosophila cell, Xenopus egg, or HeLa cells.
  • Exemplary cell-free systems include, but are not limited to, E. coli S30 Extract system, E. coli T7 S30 system, or PURExpress®.
  • a host cell includes any suitable cell such as a naturally derived cell or a genetically modified cell.
  • a host cell is a production host cell.
  • a host cell is a eukaryotic cell.
  • a host cell is a prokaryotic cell.
  • a eukaryotic cell includes fungi (e.g., yeast cells), animal cell or plant cell.
  • a prokaryotic cell is a bacterial cell. Examples of bacterial cell include gram-positive bacteria or gram-negative bacteria. Sometimes the gram-negative bacteria is anaerobic, rodshaped, or both.
  • gram-positive bacteria include Actinobacteria, Firmicutes or Tenericutes.
  • gram-negative bacteria include Aquificae, Deinococcus-Thermus, Fibrobacteres-Chlorobi/Bacteroidetes (FCB group), Fusobacteria, Gemmatimonadetes, Nitrospirae, Planctomycetes-Verrucomicrobia/ Chlamydiae (PVC group), Proteobacteria, Spirochaetes or Synergistetes.
  • bacteria can be Acidobacteria, Chloroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Dictyoglomi, Thermodesulfobacteria or Thermotogae.
  • a bacterial cell can be Escherichia coli, Clostridium botulinum, or Coli bacilli.
  • Exemplary prokaryotic host cells include, but are not limited to, BL21, MaehlTM, DH10BTM, TOP10, DH5a, DHIOBacTM, OmniMaxTM, MegaXTM, DH12STM, INV110, TOP10F’, INVaF, TOP10/P3, ccdB Survival, PIR1, PIR2, Stbl2TM, Stbl3TM, or Stbl4TM.
  • animal cells include a cell from a vertebrate or from an invertebrate.
  • an animal cell includes a cell from a marine invertebrate, fish, insects, amphibian, reptile, or mammal.
  • a fungus cell includes a yeast cell, such as brewer’s yeast, baker’s yeast, or wine yeast.
  • Fungi include ascomycetes such as yeast, mold, filamentous fungi, basidiomycetes, or zygomycetes.
  • yeast includes Ascomycota or Basidiomycota.
  • Ascomycota includes Saccharomycotina (true yeasts, e.g. Saccharomyces cerevisiae (baker’s yeast)) or Taphrinomycotina (e.g. Schizosaccharomycetes (fission yeasts)).
  • Basidiomycota includes Agaricomycotina (e.g. Tremellomycetes) or Pucciniomycotina (e.g. Microbotryomycetes).
  • Exemplary yeast or filamentous fungi include, for example, the genus: Saccharomyces, Schizosaccharomyces, Candida, Pichia, Hansenula, Kluyveromyces, Zygosaccharomyces, Yarrowia, Trichosporon, Rhodosporidi, Aspergillus, Fusarium, or Trichoderma.
  • Exemplary yeast or filamentous fungi include, for example, the species: Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida utilis, Candida boidini, Candida albicans, Candida tropicalis, Candida stellatoidea, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, Candida viswanathii, Candida lusitaniae, Rhodotorula mucilaginosa, Pichia metanolica, Pichia angusta, Pichia pastoris, Pichia anomala, Hansenula polymorpha, Kluyveromyces lactis, Zygosaccharomyces rouxii, Yarrowia lipolytica, Trichosporon pullulans, Rhodosporidium toru-Aspergillus niger, Aspergillus nidulans, Aspergillus awamori, Aspergillus ory
  • Exemplary yeast host cells include, but are not limited to, Pichia pastoris yeast strains such as GS115, KM71H, SMD1168, SMD1168H, and X-33; and Saccharomyces cerevisiae yeast strain such as INVScl.
  • additional animal cells include cells obtained from a mollusk, arthropod, annelid or sponge.
  • an additional animal cell is a mammalian cell, e.g., from a primate, ape, equine, bovine, porcine, canine, feline or rodent.
  • a rodent includes mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.
  • Exemplary mammalian host cells include, but are not limited to, 293A cell line, 293FT cell line, 293F cells , 293 H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, FUT8 KO CHOK1, Expi293FTM cells, Flp-InTM T- RExTM 293 cell line, Flp-InTM-293 cell line, Flp-InTM-3T3 cell line, Flp-InTM-BHK cell line, Flp-InTM-CHO cell line, Flp-InTM-CV-l cell line, Flp-InTM-Jurkat cell line, FreeStyleTM 293-F cells, FreeStyleTM CHO-S cells, GripTiteTM 293 MSR cell line, GS-CHO cell line, HepaRGTM cells, T-RExTM Jurkat cell line, Per.C6 cells, T- RExTM-293 cell line, T-RExTM-CHO cell line, and T-RExTM-HeLa cell line.
  • a mammalian host cell is a stable cell line, or a cell line that has incorporated a genetic material of interest into its own genome and has the capability to express the product of the genetic material after many generations of cell division.
  • a mammalian host cell is a transient cell line, or a cell line that has not incorporated a genetic material of interest into its own genome and does not have the capability to express the product of the genetic material after many generations of cell division.
  • Exemplary insect host cells include, but are not limited to, Drosophila S2 cells, Sf9 cells, Sf21 cells, High FiveTM cells, and expresSF+® cells.
  • plant cells include a cell from algae.
  • Exemplary insect cell lines include, but are not limited to, strains from Chlamydomonas reinhardtii 137c, or Synechococcus elongatus PPC 7942.
  • an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is a bispecific antibody comprising a first antigenbinding site that specifically binds to CD3 and a second antigen-binding site that specifically binds to a tumor antigen defined herein before.
  • the label or package insert indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises the bispecific antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
  • the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • BWFI bacteriostatic water for injection
  • phosphate- buffered saline such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate- buffered saline such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • antibody is used in the broadest sense and covers fully assembled antibodies, antibody fragments that can bind antigen, for example, Fab, F(ab’)2, Fv, single chain antibodies (scFv), diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, and the like.
  • CDR complementarity determining region
  • a variable region comprises three CDRs.
  • CDR peptides can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody -producing cells. See, for example, Larrick et al., Methods: A Companion to Methods in Enzymology .
  • Fab refers to a protein that contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
  • Fab’-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • Fab' fragments are produced by reducing the F(ab’)2 fragment’s heavy chain disulfide bridge. Other chemical couplings of antibody fragments are also known.
  • a “single-chain variable fragment (scFv)” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids.
  • the linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N- terminus of the VH with the C-terminus of the VL, or vice versa.
  • This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker.
  • scFv antibodies are, e.g. described in Houston, J. S., Methods in Enzymol. 203 (1991) 46-96).
  • antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.
  • Embodiment 1 comprises an isolated polypeptide or polypeptide complex comprising a peptide that impairs binding of an anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, 19-55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to an amino acid sequence selected from SEQ ID NOs: 1-2, 19-55.
  • Embodiment 2 comprises an isolated polypeptide or polypeptide complex of embodiment 1, wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55.
  • Embodiment 3 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1-2, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.
  • Embodiment 4 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1-2, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 5 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1-2, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • Embodiment 6 comprises an isolated polypeptide or polypeptide complex comprising an anti-CD3 binding domain that is linked to a peptide that impairs binding of the anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to Z1-Z2-C- Z4-P-Z6-Z7-Z8- Z9-Z10-Z11- Z12-C-Z14 and Zi is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; Z2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; Z4 is selected from G and W; Ze is selected from E, D, V, and P; Z7 is selected from W, L, F, V, G, M, I, and Y; Zg is selected from E, D, P, and Q; Z9 is selected from E, D, Y, V, F, W, P, L, and Q; Z10 is selected from S,
  • Z ⁇ is selected from F, D, Y, L, I, V, A, N, T, P, S, and H; and Z14 is selected from D, Y, N, F, I, P, V, A, T,
  • Embodiment 7 comprises an isolated polypeptide or polypeptide complex of embodiment 6, wherein Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Z10 is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Znis selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Embodiment 8 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 6-7, wherein Zi is selected from D, Y, and F; Z2 is selected from D, Y, L, and F; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, and F; Zg is selected from E and D; Z9 is selected from E and D; Z10 is selected from S, D, and Y; Zu is selected from I, Y, and F; Znis selected from F, D, Y, and L; and Z14 is selected from D, Y, and N.
  • Embodiment 9 comprises an isolated polypeptide or polypeptide complex comprising an anti-CD3 binding domain that is linked to a peptide that impairs binding of the anti-CD3 binding domain to CD3 wherein the peptide comprises an amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8- U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; Ue is selected from E, D, V, and P; U7 is selected from W, L, F, V, G, M, I, and Y; Ug is selected from E, D, P, and Q; U9 is selected from E, D, Y, V, F, W, P, L, and Q; U10 is selected from
  • Embodiment 10 comprises an isolated polypeptide or polypeptide complex of embodiment 9, wherein Ui is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; Ue is selected from E and D; U7 is selected from W, L, F, G, and V; Ug is selected from E and D; U9 is selected from E, D, Y, and V; Uio is selected from S, D, Y, T, and I; Un is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and Uu is selected from D, Y, N, F, I, M, and P.
  • Embodiment 11 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 9-
  • Ui is selected from D, Y, V, and F
  • U2 is selected from D, Y, L, and F
  • U4 is selected from G and W
  • s is selected from E and D
  • U7 is selected from W, L, G, and F
  • Us is selected from E and D
  • U9 is selected from E and D
  • Uio is selected from S, D, T, and Y
  • Un is selected from I, Y, V, L, and F
  • U12 is selected from F, D, Y, G, A, and L
  • Uu is selected from D, Y, M, and N.
  • Embodiment 12 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 6-
  • Embodiment 13 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 6- 11, wherein the peptide comprises an amino acid sequence according to any one of SEQ ID NOs: 44-55.
  • Embodiment 14 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 6 and 9-12, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 15 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 6-7 and 9-13, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • Embodiment 16 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1-15, wherein the peptide is connected to the anti-CD3 binding domain in a configuration according to Formula I: A1-L1-P1 wherein Ai comprises the anti-CD3 binding domain; Li comprises a cleavable linker that is a substrate for a tumor specific protease; Pi comprises the peptide that impairs binding of the anti-CD3 binding domain to CD3.
  • Embodiment 17 comprises an isolated polypeptide or polypeptide complex of embodiment 16, wherein Pi is connected N-terminal to the cleavable linker and Ai is connected C-terminal to the cleavable linker.
  • Embodiment 18 comprises an isolated polypeptide or polypeptide complex of embodiment 16, wherein Pi is connected C-terminal to the cleavable linker and Ai is connected N-terminal to the cleavable linker.
  • Embodiment 19 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • Pi is bound to Ai through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi- stacking interactions, or H-bonding interactions, or a combination thereof.
  • Embodiment 20 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • Ai is further linked to a tumor antigen binding domain (A2).
  • Embodiment 21 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • polypeptide or polypeptide complex is according to Formula la: P2-L2-A2-A1-L1-P1 wherein P2 comprises a peptide that impairs binding of A2 to a tumor antigen; and L2 comprises a second cleavable linker that connects A2to ?2 and is a substrate for a tumor specific protease.
  • Embodiment 22 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • Ai comprises an antibody or antibody fragment.
  • Embodiment 23 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • Embodiment 24 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 17 and 19-23, wherein Li is bound to N-terminus of the antibody or antibody fragment of Ai.
  • Embodiment 25 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16 and 18-23, wherein A2 is bound to N-terminus of the antibody or antibody fragment of Ai.
  • Embodiment 26 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16, 18-23, and 25, wherein Li is bound to the C-terminus of the antibody or antibody fragment of Ai.
  • Embodiment 27 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 17 and 19-24, wherein A2 is bound to the C-terminus of the antibody or antibody fragment of Ai.
  • Embodiment 28 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 22- 27, wherein the antibody or antibody fragment of Ai comprises a single chain variable fragment, a single domain antibody, or a Fab fragment.
  • Embodiment 29 comprises an isolated polypeptide or polypeptide complex of embodiment 28, wherein Ai is the single chain variable fragment (scFv).
  • Embodiment 30 comprises an isolated polypeptide or polypeptide complex of embodiment 29, wherein the scFv comprises a scFv heavy chain polypeptide and a scFv light chain polypeptide.
  • Embodiment 31 comprises an isolated polypeptide or polypeptide complex of embodiment 28, wherein Ai is the single domain antibody.
  • Embodiment 32 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 22- 27, wherein the antibody or antibody fragment thereof comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a came lid derived single domain antibody.
  • scFv single chain variable fragment
  • VH domain heavy chain variable domain
  • VL domain light chain variable domain
  • VHH variable domain
  • Embodiment 33 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 30 and 32, wherein Ai comprises an anti-CD3e single chain variable fragment.
  • Embodiment 34 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 32, wherein Ai comprises an anti-CD3e single chain variable fragment that has a KD binding of 1 pM or less to CD3 on CD3 expressing cells.
  • Embodiment 35 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 30 and 32-34, wherein Ai comprises a variable light chain and variable heavy chain each of which is capable of specifically binding to human CD3.
  • Embodiment 36 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 28- 30 and 32-35, wherein Ai comprises the scFv comprising a scFv heavy chain variable domain and an scFv light chain variable domain comprising complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC- CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 3; HC-CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC- CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv
  • Embodiment 37 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 30 and 32-35, wherein Ai comprises a heavy chain variable domain and a light chain variable domain comprising complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 3; HC- CDR2: SEQ ID NO: 4; HC-CDR3: SEQ ID NO: 5; and the light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO:
  • Embodiment 38 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease.
  • Embodiment 39 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-
  • polypeptide or polypeptide complex of formula I binds to an effector cell when Li is cleaved by the tumor specific protease and Ai binds to the effector cell.
  • Embodiment 40 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 38-
  • the effector cell is a T cell.
  • Embodiment 41 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 38-
  • Ai binds to a polypeptide that is part of a TCR-CD3 complex on the effector cell.
  • Embodiment 42 comprises an isolated polypeptide or polypeptide complex of embodiment 41, wherein the polypeptide that is part of the TCR-CD3 complex is human CD3a.
  • Embodiment 43 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 20- 42, wherein A2 comprises an antibody or antibody fragment.
  • Embodiment 44 comprises an isolated polypeptide or polypeptide complex of embodiment 43, wherein the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment, a single domain antibody, Fab’, or a Fab.
  • Embodiment 45 comprises an isolated polypeptide or polypeptide complex of embodiment 43, wherein the antibody or antibody fragment thereof of A2 comprises a single chain variable fragment (scFv), a heavy chain variable domain (VH domain), a light chain variable domain (VL domain), or a variable domain (VHH) of a came lid derived single domain antibody.
  • scFv single chain variable fragment
  • VH domain heavy chain variable domain
  • VL domain light chain variable domain
  • VHH variable domain
  • Embodiment 46 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 43- 45, wherein the antibody or antibody fragment thereof of A2 is humanized or human.
  • Embodiment 47 comprises an isolated polypeptide or polypeptide complex of embodiment 44, wherein A2 is the Fab or Fab’.
  • Embodiment 48 comprises an isolated polypeptide or polypeptide complex of embodiment 47, wherein the Fab or Fab’ comprises (a) a Fab light chain polypeptide and (b) a Fab heavy chain polypeptide.
  • Embodiment 49 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 20- 48, wherein A2 comprises an epidermal growth factor receptor (EGFR) binding domain.
  • Embodiment 50 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 20- 48, wherein A2 comprises a carcinoembryonic antigen-related cell adhesion molecule CEACAM5 binding domain.
  • Embodiment 51 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16- 50, wherein Pi is further linked to a half-life extending moiety (Hi).
  • Embodiment 52 comprises an isolated polypeptide or polypeptide complex of embodiment 51, wherein the half-life extending moiety is a single-domain antibody.
  • Embodiment 53 comprises an isolated polypeptide or polypeptide complex of embodiment 51, wherein Hi comprises a polymer.
  • Embodiment 54 comprises an isolated polypeptide or polypeptide complex of embodiment 53, wherein the polymer is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Embodiment 55 comprises an isolated polypeptide or polypeptide complex of embodiment 51, wherein Hi comprises albumin.
  • Embodiment 56 comprises an isolated polypeptide or polypeptide complex of embodiment 51, wherein Hi comprises an Fc domain.
  • Embodiment 57 comprises an isolated polypeptide or polypeptide complex of embodiment 55, wherein the albumin is serum albumin.
  • Embodiment 58 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 55 and 57, wherein the albumin is human serum albumin.
  • Embodiment 59 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 51- 58, wherein Hi comprises a polypeptide, a ligand, or a small molecule.
  • Embodiment 60 comprises an isolated polypeptide or polypeptide complex of embodiment 59, wherein the polypeptide, the ligand or the small molecule binds serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • Embodiment 61 comprises an isolated polypeptide or polypeptide complex of embodiment 60, wherein the serum protein comprises a thyroxine -binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the serum protein comprises a thyroxine -binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • Embodiment 62 comprises an isolated polypeptide or polypeptide complex of embodiment 60, wherein the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • Embodiment 63 comprises an isolated polypeptide or polypeptide complex of embodiment 60 or 61, wherein the serum protein is albumin.
  • Embodiment 64 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 59- 63, wherein the polypeptide is an antibody.
  • Embodiment 65 comprises an isolated polypeptide or polypeptide complex of embodiment 64, wherein the antibody comprises a single domain antibody, a single chain variable fragment, or a Fab.
  • Embodiment 66 comprises an isolated polypeptide or polypeptide complex of embodiment 65, wherein the single domain antibody comprises a single domain antibody that binds to albumin.
  • Embodiment 67 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65-
  • the single domain antibody is a human or humanized antibody.
  • Embodiment 68 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65-
  • Embodiment 69 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 67, wherein the single domain antibody is 645dsgH5gL4.
  • Embodiment 70 comprises an isolated polypeptide or polypeptide complex of embodiment 65, wherein the single domain antibody is 23-13-A01 -sc02.
  • Embodiment 71 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 66, wherein the single domain antibody is A10m3 or a fragment thereof.
  • Embodiment 72 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 66, wherein the single domain antibody is DOM7r-31.
  • Embodiment 73 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 66, wherein the single domain antibody is DOM7h-l 1-15.
  • Embodiment 74 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 66, wherein the single domain antibody is Alb-1, Alb-8, or Alb-23.
  • Embodiment 75 comprises an isolated polypeptide or polypeptide complex of embodiment 65, wherein the single domain antibody is 10G or 10GE.
  • Embodiment 76 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 65- 66, wherein the single domain antibody is SA21.
  • Embodiment 77 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1- 76, wherein the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified non-natural amino acid, or a combination thereof.
  • Embodiment 78 comprises an isolated polypeptide or polypeptide complex of embodiment 77, wherein the modified amino acid or modified non-natural amino acid comprises a post-translational modification.
  • Embodiment 79 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 51- 78, wherein Hi comprises a linking moiety (L3) that connects Hi to Pi.
  • Hi comprises a linking moiety (L3) that connects Hi to Pi.
  • Embodiment 80 comprises an isolated polypeptide or polypeptide complex of embodiment 79, wherein L3 is a peptide sequence having at least 5 to no more than 50 amino acids.
  • Embodiment 81 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79-
  • L3 is a peptide sequence having at least 10 to no more than 30 amino acids.
  • Embodiment 82 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79-
  • L3 is a peptide sequence having at least 10 amino acids.
  • Embodiment 83 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79-
  • L3 is a peptide sequence having at least 18 amino acids.
  • Embodiment 84 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79-
  • Embodiment 85 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79- 84, wherein Lshas a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918).(GGGGS) n (SEQ ID NO: 919).and(GSSGGS) n (SEQ ID NO: 920). wherein n is an integer of at least 1.
  • Embodiment 86 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 79- 84, wherein L3 comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • Embodiment 87 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, wherein the Fab light chain polypeptide of A2 is bound to a C-terminus of the single chain variable fragment (scFv) of Ai.
  • scFv single chain variable fragment
  • Embodiment 88 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, wherein the Fab heavy chain polypeptide of A2 is bound to a C-terminus of the single chain variable fragment (scFv) Ai.
  • Embodiment 89 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, wherein the Fab light chain polypeptide of A2 is bound to a N-terminus of the single chain variable fragment (scFv) of Ai.
  • scFv single chain variable fragment
  • Embodiment 90 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, wherein the Fab heavy chain polypeptide of A2 is bound to a N-terminus of the single chain variable fragment (scFv) Ai.
  • Embodiment 91 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, 88, and 90, wherein the Fab heavy chain polypeptide of A2is bound to the scFv heavy chain polypeptide of Ai.
  • Embodiment 92 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, 87, and 89, wherein the Fab light chain polypeptide of A2 is bound to the scFv heavy chain polypeptide of Ai.
  • Embodiment 93 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, 88, and 90, wherein the Fab heavy chain polypeptide of A2is bound to the scFv light chain polypeptide of Ai.
  • Embodiment 94 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48- 86, 87, and 89, wherein the Fab light chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai.
  • Embodiment 95 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48-
  • Embodiment 96 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 48-
  • Embodiment 97 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1- 86, 88, 90, and 93, wherein the Fab heavy chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab light chain polypeptide of A2.
  • Embodiment 98 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 1- 87, 89, and 94, wherein the Fab light chain polypeptide of A2 is bound to the scFv light chain polypeptide of Ai and L2 is bound to the Fab heavy chain polypeptide of A2.
  • Embodiment 99 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21- 98, wherein P2 impairs binding of A2to the tumor antigen.
  • Embodiment 100 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-99, wherein P2 is bound to A2 through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi- stacking interactions, or H-bonding interactions, or a combination thereof.
  • Embodiment 101 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-100, wherein P2 is bound to A2 at or near an antigen binding site.
  • Embodiment 102 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-101, wherein P2 has less than 70% sequence homology to the tumor antigen.
  • Embodiment 103 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-102, wherein P2 comprises a peptide sequence of at least 10 amino acids in length.
  • Embodiment 104 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-103, wherein P2 comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length.
  • Embodiment 105 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-104, wherein P2 comprises a peptide sequence of at least 16 amino acids in length.
  • Embodiment 106 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-103 and 105, wherein P2 comprises a peptide sequence of no more than 40 amino acids in length.
  • Embodiment 107 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-106, wherein P2comprises at least two cysteine amino acid residues.
  • Embodiment 108 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-107, wherein P2 comprises a cyclic peptide or a linear peptide.
  • Embodiment 109 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-108, wherein P2 comprises a cyclic peptide.
  • Embodiment 110 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-108, wherein P2comprises a linear peptide.
  • Embodiment 111 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-17, 19-24, 27-88, and 91-110, wherein Li is bound to N-terminus of Ai.
  • Embodiment 112 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16, 18-23, 25-26, 28-86, 89-110, wherein Li is bound to C-terminus of Ai.
  • Embodiment 113 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-23, 25-26, 28-86, 89-110, and 112, wherein L2 is bound to N-terminus of A2.
  • Embodiment 114 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21, 24, 27-88, and 91-111, wherein L2 is bound to C-terminus of A2.
  • Embodiment 115 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-114, wherein Li or L2 is a peptide sequence having at least 5 to no more than 50 amino acids.
  • Embodiment 116 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-115, wherein Li or L2 is a peptide sequence having at least 10 to no more than 30 amino acids.
  • Embodiment 117 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-116, wherein Li or L2 is a peptide sequence having at least 10 amino acids.
  • Embodiment 118 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-117, wherein Li or L2is a peptide sequence having at least 18 amino acids.
  • Embodiment 119 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-118, wherein Li or L2 is a peptide sequence having at least 26 amino acids .
  • Embodiment 120 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-115, wherein Li or L2has a formula comprising (G2S) n (SEQ ID NO: 922), wherein n is an integer from 1 to 3.
  • Embodiment 121 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-120, wherein Li has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920) wherein n is an integer of at least 1.
  • Embodiment 122 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-121, wherein Pi becomes unbound from Ai when Li is cleaved by the tumor specific protease thereby exposing Ai to CD3.
  • Embodiment 123 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 21-122, wherein P2 becomes unbound from A2 when L2 is cleaved by the tumor specific protease thereby exposing A2 to the tumor antigen.
  • Embodiment 124 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-123, wherein the tumor specific protease is selected from the group consisting of metalloprotease, serine protease, cysteine protease, threonine protease, and aspartic protease.
  • Embodiment 125 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-124, wherein Li or L2 comprises a urokinase cleavable amino acid sequence, a matriptase cleavable amino acid sequence, a matrix metalloprotease cleavable amino acid sequence, or a legumain cleavable amino acid sequence.
  • Embodiment 126 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-119 and 122-125, wherein Li or L2 comprises an amino acid sequence selected from the group consisting of GGGGSLSGRSDNHGSSGT (SEQ ID NO: 923), GGGGSSGGSGGSGLSGRSDNHGSSGT (SEQ ID NO: 924), ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), ISSGLLAGRSDNH (SEQ ID NO: 928), LSGRSDNH (SEQ ID NO: 929), ISSGLLSGRSDNP (SEQ ID NO: 930), ISSGLLSGRSDNH (SEQ ID NO: 931), LSGRSDNHSPLGLAGS (SEQ ID NO: 932), SPLGLAGSLSGRSDNH (SEQ ID NO: 933), SPLGLSGRSDNH (SEQ ID NO: 934), LAGRSDNHSPLGLA
  • Embodiment 127 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 16-119 and 122-126, wherein Li or L2 comprises an amino acid sequence selected from the group consisting of ASGRSDNH (SEQ ID NO: 925), LAGRSDNH (SEQ ID NO: 926), ISSGLASGRSDNH (SEQ ID NO: 927), and ISSGLLAGRSDNH (SEQ ID NO: 928).
  • ASGRSDNH SEQ ID NO: 925
  • LAGRSDNH SEQ ID NO: 926
  • ISSGLASGRSDNH SEQ ID NO: 927
  • ISSGLLAGRSDNH SEQ ID NO: 928
  • Embodiment 128 comprises a pharmaceutical composition comprising: (i) the polypeptide or polypeptide complex of any one of embodiments 1-127; and (ii) a pharmaceutically acceptable excipient.
  • Embodiment 129 comprises an isolated recombinant nucleic acid molecule encoding the polypeptide or polypeptide complex of any one of embodiments 1-127.
  • Embodiment 130 comprises an isolated polypeptide or polypeptide complex according to Formula II: Li a - Pia-Hi a wherein: Li a comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pi a to an anti-CD3 binding domain that binds to CD3 and; Pi a comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Li a is uncleaved wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55 or the peptide comprises 1, 2, or 3, amino acid substitutions, additions, or deletions relative to amino acid sequences of SEQ ID NOs: 1-2, and 19-55; and Hi a comprises a half-life extending molecule.
  • Embodiment 131 comprises an isolated polypeptide or polypeptide complex of embodiment 130, wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 1-2, and 19-55
  • Embodiment 132 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-131, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.
  • Embodiment 133 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-131, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 134 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-131, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 54.
  • Embodiment 135 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-134, wherein Hi a comprises a polymer.
  • Embodiment 136 comprises an isolated polypeptide or polypeptide complex of embodiment 135, wherein the polymer is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Embodiment 137 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-134, wherein Hi a comprises albumin.
  • Embodiment 138 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-134, wherein Hi a comprises an Fc domain.
  • Embodiment 139 comprises an isolated polypeptide or polypeptide complex of embodiment 137, wherein the albumin is serum albumin.
  • Embodiment 140 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 137 and 139, wherein the albumin is human serum albumin.
  • Embodiment 141 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-140, wherein Hi a comprises a polypeptide, a ligand, or a small molecule.
  • Embodiment 142 comprises an isolated polypeptide or polypeptide complex of embodiment 141, wherein the polypeptide, the ligand or the small molecule binds a serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • Embodiment 143 comprises an isolated polypeptide or polypeptide complex of embodiment 142, wherein the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • Embodiment 144 comprises an isolated polypeptide or polypeptide complex of embodiment 142, wherein the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • Embodiment 145 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 142-143, wherein the serum protein is albumin.
  • Embodiment 146 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 141-145, wherein the polypeptide is an antibody.
  • Embodiment 147 comprises an isolated polypeptide or polypeptide complex of embodiment 146, wherein the antibody comprises a single domain antibody, a single chain variable fragment or a Fab.
  • Embodiment 148 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 146-147, wherein the antibody comprises a single domain antibody that binds to albumin.
  • Embodiment 149 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • the antibody is a human or humanized antibody.
  • Embodiment 150 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • Embodiment 151 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-149, wherein the single domain antibody is 645dsgH5gL4.
  • Embodiment 152 comprises an isolated polypeptide or polypeptide complex of embodiment 147, wherein the single domain antibody is 23-13-A01 -sc02.
  • Embodiment 153 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-148, wherein the single domain antibody is A10m3 or a fragment thereof.
  • Embodiment 154 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-148, wherein the single domain antibody is DOM7r-31.
  • Embodiment 155 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-148, wherein the single domain antibody is DOM7h-l 1-15.
  • Embodiment 156 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-148, wherein the single domain antibody is Alb-1, Alb-8, or Alb-23.
  • Embodiment 157 comprises an isolated polypeptide or polypeptide complex of embodiment 147, wherein the single domain antibody is 10G or 10GE.
  • Embodiment 158 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 147-148, wherein the single domain antibody is SA21.
  • Embodiment 159 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 130-158, wherein Hi a comprises a linking moiety (Lsa) that connects Hi a to Pi a .
  • Lsa linking moiety
  • Embodiment 160 comprises an isolated polypeptide or polypeptide complex of embodiment 159, wherein L3 a is a peptide sequence having at least 5 to no more than 50 amino acids.
  • Embodiment 161 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-160, wherein L3 a is a peptide sequence having at least 10 to no more than 30 amino acids.
  • Embodiment 162 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-161, wherein L3 a is a peptide sequence having at least 10 amino acids.
  • Embodiment 163 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-162, wherein L3 a is a peptide sequence having at least 18 amino acids.
  • Embodiment 164 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-163, wherein L3 a is a peptide sequence having at least 26 amino acids.
  • Embodiment 165 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-164, wherein L3 a has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920) wherein n is an integer of at least 1.
  • Embodiment 166 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 159-164, wherein L3 a comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • Embodiment 167 comprises an isolated polypeptide or polypeptide complex according to Formula III: Lib- Pib-Hib wherein: Lib comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pib to an anti-CD3 binding domain that binds to CD3 and; Pib comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Lib is uncleaved wherein the peptide comprises the amino acid sequence according to Z1-Z2-C- Z4-P-Z6-Z7-Z8- Z9-Z10-Z11- Z12-C-Z14 and Zi is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; Z2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; Z4 is selected from G and W; Ze is selected from E, D, V, and P; Z7 is selected from W, L
  • Embodiment 168 comprises an isolated polypeptide or polypeptide complex of embodiment 167, wherein Zi is selected from D, Y, F, I, and N; Z2 is selected from D, Y, L, F, I, and N; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, F, and V; Zg is selected from E and D; Z9 is selected from E, D, Y, and V; Z10 is selected from S, D, Y, T, and I; Zu is selected from I, Y, F, V, L, and T; Z12 is selected from F, D, Y, L, I, V, A, and N; and Z14 is selected from D, Y, N, F, I, and P.
  • Embodiment 169 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-168, wherein Zi is selected from D, Y, and F; Z2 is selected from D, Y, L, and F; Z4 is selected from G and W; Ze is selected from E and D; Z7 is selected from W, L, and F; Zg is selected from E and D; Z9 is selected from E and D; Zio is selected from S, D, and Y; Zu is selected from I, Y, and F; Z12 is selected from F, D, Y, and L; and Z14 is selected from D, Y, and N.
  • Embodiment 170 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-169, wherein PH, comprises comprises an amino acid sequence of Table 17.
  • Embodiment 171 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-170, wherein PH, comprises an amino acid sequences according to any one of SEQ ID NOs: 44-55.
  • Embodiment 172 comprises an isolated polypeptide or polypeptide complex of embodiment 167, wherein Pib comprises the amino acid sequences according to SEQ ID NO: 2.
  • Embodiment 173 comprises an isolated polypeptide or polypeptide complex of embodiment 167-168, wherein Pn> comprises the amino acid sequences according to SEQ ID NO: 54.
  • Embodiment 174 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-173, wherein Hib comprises a polymer.
  • Embodiment 175 comprises an isolated polypeptide or polypeptide complex of embodiment 174, wherein the polymer is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Embodiment 176 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-173, wherein Hib comprises albumin.
  • Embodiment 177 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-173, wherein Hib comprises an Fc domain.
  • Embodiment 178 comprises an isolated polypeptide or polypeptide complex of embodiment 176, wherein the albumin is serum albumin.
  • Embodiment 179 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 176 and 178, wherein the albumin is human serum albumin.
  • Embodiment 180 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-179, wherein Hib comprises a polypeptide, a ligand, or a small molecule.
  • Embodiment 181 comprises an isolated polypeptide or polypeptide complex of embodiment 180, wherein the polypeptide, the ligand or the small molecule binds a serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • Embodiment 182 comprises an isolated polypeptide or polypeptide complex of embodiment 181, wherein the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • Embodiment 183 comprises an isolated polypeptide or polypeptide complex of embodiment 181, wherein the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • Embodiment 184 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 181-182, wherein the serum protein is albumin.
  • Embodiment 185 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 180-184, wherein the polypeptide is an antibody.
  • Embodiment 186 comprises an isolated polypeptide or polypeptide complex of embodiment 185, wherein the antibody comprises a single domain antibody, a single chain variable fragment or a Fab.
  • Embodiment 187 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 185-186, wherein the antibody comprises a single domain antibody that binds to albumin.
  • Embodiment 188 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • the antibody is a human or humanized antibody.
  • Embodiment 189 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-188, wherein the single domain antibody is 645gHlgLl.
  • Embodiment 190 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • Embodiment 191 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186, wherein the single domain antibody is 23-13-A01 -sc02.
  • Embodiment 192 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-187, wherein the single domain antibody is A10m3 or a fragment thereof.
  • Embodiment 193 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-187, wherein the single domain antibody is DOM7r-31.
  • Embodiment 194 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-187, wherein the single domain antibody is DOM7h-l 1-15.
  • Embodiment 195 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-187, wherein the single domain antibody is Alb-1, Alb-8, or Alb-23.
  • Embodiment 196 comprises an isolated polypeptide or polypeptide complex of embodiment 186, wherein the single domain antibody is 10G or 10GE.
  • Embodiment 197 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 186-187, wherein the single domain antibody is SA21.
  • Embodiment 198 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 167-197, wherein Hib comprises a linking moiety (Lsb) that connects Hib to Pib.
  • Hib comprises a linking moiety (Lsb) that connects Hib to Pib.
  • Embodiment 199 comprises an isolated polypeptide or polypeptide complex of embodiment 198, wherein L’,b is a peptide sequence having at least 5 to no more than 50 amino acids.
  • Embodiment 200 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-199, wherein L , is a peptide sequence having at least 10 to no more than 30 amino acids.
  • Embodiment 201 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-200, wherein L , is a peptide sequence having at least 10 amino acids.
  • Embodiment 202 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-201, wherein L , is a peptide sequence having at least 18 amino acids.
  • Embodiment 203 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-202, wherein L , is a peptide sequence having at least 26 amino acids.
  • Embodiment 204 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-203, wherein L ⁇ has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920) wherein n is an integer of at least 1.
  • Embodiment 205 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 198-203, wherein L , comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • Embodiment 206 comprises an isolated polypeptide or polypeptide complex according to Formula IV: Li c - Pic-Hic wherein: Li c comprises a tumor specific protease-cleaved linking moiety that when uncleaved connects Pi c to an anti-CD3 binding domain that binds to CD3 and; Pi c comprises a peptide that impairs binding of the anti-CD3 binding domain to CD3 when Lib is uncleaved wherein the peptide comprises the amino acid sequence according to U1-U2-C- U 4 -P-U 6 -U 7 -U 8 - U9-U10-U11- U12-C-U14 and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U 2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; Ue is selected from E, D, V, and
  • Embodiment 207 comprises an isolated polypeptide or polypeptide complex of embodiment 206, wherein Ui is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; Us is selected from E and D; U7 is selected from W, L, F, G, and V; U 8 is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; Un is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and U» is selected from D, Y, N, F, I, M, and P.
  • Embodiment 208 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-207, wherein Ui is selected from D, Y, V, and F; U2 is selected from D, Y, L, and F; U4 is selected from G and W; U 6 is selected from E and D; U7 is selected from W, L, G, and F; U 8 is selected from E and D; U9 is selected from E and D; U10 is selected from S, D, T, and Y; Un is selected from I, Y, V, L, and F; U12 is selected from F, D, Y, G, A, and L; and U» is selected from D, Y, M, and N.
  • Embodiment 209 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-208, wherein Pi c comprises comprises an amino acid sequence of Table 17.
  • Embodiment 210 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-209, wherein Pi c comprises an amino acid sequences according to any one of SEQ ID NOs: 44-55.
  • Embodiment 211 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-209, wherein Pi c comprises the amino acid sequences according to SEQ ID NO: 2.
  • Embodiment 212 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-210, wherein Pi c comprises the amino acid sequences according to SEQ ID NO: 54.
  • Embodiment 213 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-212, wherein Hi c comprises a polymer.
  • Embodiment 214 comprises an isolated polypeptide or polypeptide complex of embodiment 213, wherein the polymer is polyethylene glycol (PEG).
  • Embodiment 215 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-212, wherein Hi c comprises albumin.
  • Embodiment 216 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-212, wherein Hi c comprises an Fc domain.
  • Embodiment 217 comprises an isolated polypeptide or polypeptide complex of embodiment 215, wherein the albumin is serum albumin.
  • Embodiment 218 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 215 and 217, wherein the albumin is human serum albumin.
  • Embodiment 219 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-218, wherein Hi c comprises a polypeptide, a ligand, or a small molecule.
  • Embodiment 220 comprises an isolated polypeptide or polypeptide complex of embodiment 219, wherein the polypeptide, the ligand or the small molecule binds a serum protein or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35/CR1.
  • Embodiment 221 comprises an isolated polypeptide or polypeptide complex of embodiment 220, wherein the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • the serum protein comprises a thyroxine-binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin.
  • Embodiment 222 comprises an isolated polypeptide or polypeptide complex of embodiment 220, wherein the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD.
  • Embodiment 223 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 220-221, wherein the serum protein is albumin.
  • Embodiment 224 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 219-223, wherein the polypeptide is an antibody.
  • Embodiment 225 comprises an isolated polypeptide or polypeptide complex of embodiment 224, wherein the antibody comprises a single domain antibody, a single chain variable fragment or a Fab.
  • Embodiment 226 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 224-225, wherein the antibody comprises a single domain antibody that binds to albumin.
  • Embodiment 227 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • the antibody is a human or humanized antibody.
  • Embodiment 228 comprises an isolated polypeptide or polypeptide complex of any one of embodiments
  • Embodiment 229 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-227, wherein the single domain antibody is 645dsgH5gL4.
  • Embodiment 230 comprises an isolated polypeptide or polypeptide complex of embodiment 225, wherein the single domain antibody is 23-13-A01 -sc02.
  • Embodiment 231 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-226, wherein the single domain antibody is A10m3 or a fragment thereof.
  • Embodiment 232 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-226, wherein the single domain antibody is DOM7r-31.
  • Embodiment 233 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-226, wherein the single domain antibody is DOM7h-l 1-15.
  • Embodiment 234 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-226, wherein the single domain antibody is Alb-1, Alb-8, or Alb-23.
  • Embodiment 235 comprises an isolated polypeptide or polypeptide complex of embodiment 225, wherein the single domain antibody is 10G or 10GE.
  • Embodiment 236 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 225-226, wherein the single domain antibody is SA21.
  • Embodiment 237 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 206-236, wherein Hi c comprises a linking moiety (L, c ) that connects Hi c to Pi c .
  • Embodiment 238 comprises an isolated polypeptide or polypeptide complex of embodiment 237, wherein L c is a peptide sequence having at least 5 to no more than 50 amino acids.
  • Embodiment 239 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-238, wherein L; c is a peptide sequence having at least 10 to no more than 30 amino acids.
  • Embodiment 240 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-239, wherein L; c is a peptide sequence having at least 10 amino acids.
  • Embodiment 241 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-240, wherein L; c is a peptide sequence having at least 18 amino acids.
  • Embodiment 242 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-241, wherein L; c is a peptide sequence having at least 26 amino acids.
  • Embodiment 243 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-242, wherein L; c has a formula selected from the group consisting of (G2S) n , (GS) n , (GSGGS) n (SEQ ID NO: 917), (GGGS)n (SEQ ID NO: 918), (GGGGS) n (SEQ ID NO: 919),and (GSSGGS) n (SEQ ID NO: 920) wherein n is an integer of at least 1.
  • Embodiment 244 comprises an isolated polypeptide or polypeptide complex of any one of embodiments 237-242, wherein L’, c comprises an amino acid sequence according to (GGGGSGGGS (SEQ ID NO: 921)).
  • Example 1 Structure activity relationships for Peptide-1 and Peptide 2 by Ala scanning
  • Peptides were evaluated fortheir ability to bind SP34.185 scFv by standard enzyme linked immunosorbent assays (ELISAs). Briefly, biotinylated peptides were captured on neutravidin coated plates, quench with biocytin followed by a washing step. SP34. 185 scFv was then titrated onto the peptide captured plates. Plates were then washed and bound SP34. 185 scFv was detected using a secondary horse radish peroxidase antibody conjugate. After washing again, plates were developed using standard ELISA techniques and stopped using acid. The concentration of SP34.185 scFv required to achieve 50% maximal signal or EC50 was calculated using Graphpad prism. Data is shown in Figs. 1A-1F.
  • Example 2 Polypeptide binding to CD3 by ELISA
  • Peptide masks were incorporated into bispecific polypeptide molecules via tethering to SP34. 185 scFv using a cleavable linker. Polypeptide molecules were then evaluated for their ability to bind CD3 before and after protease treatment via standard enzyme linked immunosorbent assays (ELISAs). Briefly, biotinylated CD3 was captured on neutravidin coated plates, quenched with biocytin, and washed. Polypeptide molecules were treated with protease when indicated. Polypeptide molecules were then titrated in buffer and added to the CD3 captured ELISA plate.
  • ELISAs enzyme linked immunosorbent assays
  • Example 3 Polypeptide mediated tumor cell killing
  • Peptide masks were incorporated into bispecific polypeptide molecules via tethering to SP34. 185 scFv using a cleavable linker. Bispecific polypeptide molecules’ functional activities were then evaluated before and after protease treatment via tumor cell line killing assays. Tumor cell killing was measured using an xCelligence real time cell analyzer (RTCA from Agilent) that relies on surface impedance to monitor cell growth kinetics. Briefly, tumor cell lines were seeded on E-plates and allowed to adhere overnight in a humidified incubator at 37C with 5% carbon dioxide atmosphere. After the overnight incubation, bispecific polypeptide molecules were titrated in cell culture medium and added to the plates.
  • RTCA real time cell analyzer
  • effector cells such as PBMCs or CD8+ T cells were added to the plate at the indicated effector cell to tumor cell ratio.
  • Bispecific polypeptides were treated with protease when indicated. Plates were then placed back on the RTCA inside the humidified incubator and impedance measurements (cell index) collected every lOminutes for multiple days. After multiple days, the area under the tumor growth curves (cell index times hours) were plotted against the logarithmic concentration of polypeptide molecule. The concentration of polypeptide molecule required to inhibit tumor cell growth by 50% (IC50) was calculated in Graphpad Prism. Masking of the polypeptide binding domains significantly inhibited functional tumor killing while treatment of masked polypeptides with protease restored functional tumor killing.
  • DNA oligo libraries were constructed where codons encoding critical residues within each peptide sequence were minimally mutated and codons encoding non-critical residues were heavily mutated.
  • the resulting oligos were cloned into bacteriophage vectors used to display the SAR guided peptides via fusion to the pill filament of the bacteriophage.
  • the relevant vectors were then used to produce the phage optimization libraries via amplification in bacteria using standard techniques in the field.
  • Example 5 Panning of the optimized phage library
  • phage libraries were bio-panned using SP34.185 scFv loaded beads. Multiple rounds of panning were performed where bacteriophage was allowed to bind to SP34.185 scFv loaded beads, washed, eluted, and amplified. Additional selective pressure was included during each round of panning using a fixed concentration of CD3, peptide- 1, or peptide-2. After panning, phage infected bacteria were plated out and colonies picked into 96 well blocks. Clonal phage was then amplified and separated from bacterial cells via centrifugation. Phage containing supernatants were tested in binding ELISAs against SP34. 185 scFv coated plates in the presence or absence of saturating concentration of CD3. Phage able to bind SP34.185 scFv were selected for sequence analysis if the binding signal was reduced in the presence of CD3.
  • Clonal phage were harvested as crude supernatants and screened via standard enzyme linked immunsorbent assays (ELISAs). Briefly, biotinylated SP34.185 scFv was captured on neutravidin coated plates. Prior to the addition of clonal phage, wells were incubated with blocking buffer and CD3 or blocking buffer alone. Without washing or aspirating, clonal phage supernatants were then added to the wells and incubated for a short time. Wells were then washed followed by detection of bound phage using a horse radish peroxidase conjugated anti-M13 antibody. Clonal phage of interest were then sent for sequence analysis.
  • ELISAs enzyme linked immunsorbent assays
  • Peptide-29 to Peptide-40 were selected for sequence analysis and sequences are shown in Table 18.
  • Peptide binding to SP34.185 scFv to CD3 is shown in Figs. 5A-5B and summarized in Tables 19-20, respectively.
  • Peptide inhibition of SP34.185 scFv binding to CD3 by ELISA is shown in Figs. 6A-6B and summarized in Tables 21-22, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2021/062233 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains Ceased WO2022125562A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2023534635A JP2024500335A (ja) 2020-12-08 2021-12-07 抗ｃｄ３結合ドメインのためのペプチド組成物および方法
MX2023006733A MX2023006733A (es) 2020-12-08 2021-12-07 Composiciones de peptidos y metodos para dominios de union anti-cd3.
US18/256,278 US20240043536A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains
EP21904260.3A EP4259177A4 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains
CA3201401A CA3201401A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains
AU2021396507A AU2021396507A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains
KR1020237023034A KR20230137301A (ko) 2020-12-08 2021-12-07 항-cd3 결합 도메인에 대한 펩타이드 조성물 및 방법
CN202180092543.9A CN116981682A (zh) 2020-12-08 2021-12-07 用于抗-cd3结合结构域的肽组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122820P 2020-12-08 2020-12-08
US63/122,820 2020-12-08

Publications (1)

Publication Number Publication Date
WO2022125562A1 true WO2022125562A1 (en) 2022-06-16

Family

ID=81973732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/062233 Ceased WO2022125562A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains

Country Status (9)

Country Link
US (1) US20240043536A1 (https=)
EP (1) EP4259177A4 (https=)
JP (1) JP2024500335A (https=)
KR (1) KR20230137301A (https=)
CN (1) CN116981682A (https=)
AU (1) AU2021396507A1 (https=)
CA (1) CA3201401A1 (https=)
MX (1) MX2023006733A (https=)
WO (1) WO2022125562A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11555078B2 (en) 2020-12-09 2023-01-17 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
WO2024102723A3 (en) * 2022-11-10 2024-06-20 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
US12161724B2 (en) 2020-04-04 2024-12-10 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof
US12617865B2 (en) 2022-11-16 2026-05-05 Janux Therapeutics, Inc. Activated antibodies targeting PSMA and effector cell antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190070248A1 (en) * 2015-07-14 2019-03-07 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MX2023013382A (es) * 2020-04-04 2024-01-30 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
EP4259202A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. COMPOSITIONS AND METHODS RELATED TO TUMOR-ACTIVATED ANTIBODIES AGAINST TROP2 AND EFFECTOR CELL ANTIGENS
AU2021396172A1 (en) * 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190070248A1 (en) * 2015-07-14 2019-03-07 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProtKB [online] 13 April 2016 (2016-04-13), "Acidibacillus ferrooxidans ATW55_11625 gene Uncharacterized protein", Database accession no. A0A101XTH3_9BACL *
See also references of EP4259177A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161724B2 (en) 2020-04-04 2024-12-10 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US12433953B2 (en) 2020-04-04 2025-10-07 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US11555078B2 (en) 2020-12-09 2023-01-17 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
WO2024102723A3 (en) * 2022-11-10 2024-06-20 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
US12617865B2 (en) 2022-11-16 2026-05-05 Janux Therapeutics, Inc. Activated antibodies targeting PSMA and effector cell antigens
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Also Published As

Publication number Publication date
MX2023006733A (es) 2023-08-14
JP2024500335A (ja) 2024-01-09
CA3201401A1 (en) 2022-06-16
CN116981682A (zh) 2023-10-31
AU2021396507A1 (en) 2023-07-06
EP4259177A4 (en) 2024-11-06
US20240043536A1 (en) 2024-02-08
EP4259177A1 (en) 2023-10-18
KR20230137301A (ko) 2023-10-04

Similar Documents

Publication Publication Date Title
US20240043536A1 (en) Peptide compositions and methods for anti-cd3 binding domains
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US11555078B2 (en) Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
US20240034814A1 (en) Half-life extending compositions and methods
EP4259202A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
WO2022240865A1 (en) Antibodies targeting egfr and cd3 and uses thereof
US20250250339A1 (en) Antibodies targeting egfr and cd3 and uses thereof
WO2022081822A1 (en) Antibodies targeting psma and cd3 and uses thereof
US12617865B2 (en) Activated antibodies targeting PSMA and effector cell antigens
WO2026096559A1 (en) Antibodies for targeting psma and uses thereof
WO2025097024A1 (en) Antibodies for targeting cd28 and uses thereof
HK40102719A (zh) 用於抗-cd3结合结构域的肽组合物和方法
WO2026096557A2 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022087211A1 (en) Antibodies targeting her2 and cd3 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21904260

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3201401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023534635

Country of ref document: JP

Ref document number: MX/A/2023/006733

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023011312

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021396507

Country of ref document: AU

Date of ref document: 20211207

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021904260

Country of ref document: EP

Effective date: 20230710

WWE Wipo information: entry into national phase

Ref document number: 202180092543.9

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023011312

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, TRADUCAO COMPLETA DO PEDIDO, ADAPTADA A NORMAVIGENTE, CONFORME CONSTA NO DEPOSITO INTERNACIONAL INICIAL PCT US2021/062233 DE 07/12/2021,POIS A MESMA NAO FOI APRESENTADA ATE O MOMENTO.

ENP Entry into the national phase

Ref document number: 112023011312

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230607

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112023011312

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2746 DE 22/08/2023 POR TER SIDO INDEVIDA.